China Biologic Products 20-F 6 Mar 19 2018 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2018shares
Document and Entity Information [Abstract]
Document Type	20-F
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY
Entity Registrant Name	China Biologic Products Holdings, Inc.
Entity Central Index Key	1,369,868
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Trading Symbol	CBPO
Entity Common Stock, Shares Outstanding	39,361,616
Entity Shell Company	false
Entity Emerging Growth Company	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current Assets
Cash and cash equivalents	$ 338,880,559	$ 219,336,848
Time deposits	537,478,040	22,895,200
Short term investments	76,048,594	0
Accounts receivable, net of allowance for doubtful accounts	125,115,842	77,267,275
Loan receivable - current	0	45,912,000
Inventories	243,295,512	209,570,835
Prepayments and other current assets, net of allowance for doubtful accounts	36,369,275	18,139,453
Total Current Assets	1,357,187,822	593,121,611
Property, plant and equipment, net	178,327,361	166,812,749
Intangible assets, net	53,258,871	536,338
Land use rights, net	32,204,342	24,853,163
Equity method investment	15,428,028	14,903,908
Prepayments for investments in equity securities	10,812,893	0
Loan receivable - non current	39,942,591	0
Goodwill	313,588,803	0
Other non-current assets	9,227,970	8,829,648
Total Assets	2,009,978,681	809,057,417
Current Liabilities
Accounts payable	11,404,642	7,548,909
Income tax payable	11,010,347	14,258,544
Other payables and accrued expenses	99,933,793	75,827,864
Total Current Liabilities	122,348,782	97,635,317
Deferred income	2,824,212	3,476,877
Non-current income tax payable	26,899,038	37,067,138
Other liabilities	13,203,485	6,553,088
Total Liabilities	165,275,517	144,732,420
Shareholders' Equity
Ordinary share: par value $0.0001; 100,000,000 shares authorized; 41,616,320 and 29,866,545 shares issued at December 31, 2018 and 2017, respectively; 39,361,616 and 27,611,841 shares outstanding at December 31, 2018 and 2017, respectively	4,162	2,987
Additional paid-in capital	1,189,698,494	140,230,395
Treasury share: 2,254,704 shares at December 31, 2018 and 2017, respectively, at cost	(56,425,094)	(56,425,094)
Retained earnings	634,482,738	506,426,436
Accumulated other comprehensive (losses)/income	(45,710,701)	7,957,304
Total equity attributable to China Biologic Products Holdings, Inc.	1,722,049,599	598,192,028
Noncontrolling interest	122,653,565	66,132,969
Total Shareholders' Equity	1,844,703,164	664,324,997
Commitments and contingencies
Total Liabilities and Shareholders' Equity	$ 2,009,978,681	$ 809,057,417

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Common Stock, Par Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	41,616,320	29,866,545
Common Stock, Shares, Outstanding	39,361,616	27,611,841
Treasury Stock, Shares	2,254,704	2,254,704

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Sales	$ 466,877,569	$ 370,406,840	$ 341,169,426
Cost of sales	146,787,236	125,517,021	124,034,448
Gross profit	320,090,333	244,889,819	217,134,978
Operating expenses
Selling expenses	95,575,830	34,843,935	11,679,242
General and administrative expenses	68,817,340	67,683,667	54,519,122
Research and development expenses	9,524,412	6,503,712	7,021,992
Income from operations	146,172,751	135,858,505	143,914,622
Other income (expenses)
Equity in income of an equity method investee	2,368,995	3,509,071	2,519,201
Interest income	13,706,750	7,623,624	7,815,780
Interest expense	(338,136)	(583,432)	(254,471)
Loss from disposal of a subsidiary	0	0	(75,891)
Other income, net	4,092,935	0	0
Total other income, net	19,830,544	10,549,263	10,004,619
Income before income tax expense	166,003,295	146,407,768	153,919,241
Income tax expense	18,036,180	64,171,809	25,125,820
Net income	147,967,115	82,235,959	128,793,421
Less: Net income attributable to noncontrolling interest	19,910,813	14,292,924	24,014,114
Net income attributable to China Biologic Products Holdings, Inc.	$ 128,056,302	$ 67,943,035	$ 104,779,307
Earnings per share of ordinary share:
Basic	$ 3.54	$ 2.40	$ 3.79
Diluted	$ 3.53	$ 2.38	$ 3.74
Weighted average shares used in computation:
Basic	35,304,294	27,361,561	26,848,445
Diluted	35,432,959	27,605,623	27,249,144
Net income	$ 147,967,115	$ 82,235,959	$ 128,793,421
Other comprehensive (losses)/income:
Foreign currency translation adjustment, net of nil income taxes	(60,783,829)	36,861,394	(31,303,262)
Comprehensive income	87,183,286	119,097,353	97,490,159
Less: Comprehensive income attributable to noncontrolling interest	12,794,989	17,876,743	19,026,592
Comprehensive income attributable to China Biologic Products Holdings, Inc.	$ 74,388,297	$ 101,220,610	$ 78,463,567

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)	Total	Ordinary share [Member]	Additional paid-in capital [Member]	Treasury stock [Member]	Retained earnings [Member]	Accumulated other comprehensive income (loss) [Member]	Equity attributable to China Biologic Products Holdings, Inc. [Member]	Noncontrolling interest [Member]
Balance at Dec. 31, 2015	$ 466,961,799	$ 2,884	$ 105,079,845	$ (56,425,094)	$ 333,704,094	$ (18,605)	$ 382,343,124	$ 84,618,675
Balance (in shares) at Dec. 31, 2015		28,835,053
Net income	128,793,421	$ 0	0	0	104,779,307	0	104,779,307	24,014,114
Other comprehensive income (loss)	(31,303,262)	0	0	0	0	(26,315,740)	(26,315,740)	(4,987,522)
Dividend declared to a noncontrolling interest shareholder	(10,901,312)	0	0	0	0	0	0	(10,901,312)
Share-based compensation	24,405,511	0	24,405,511	0	0	0	24,405,511	0
Excess tax benefits from stock option exercises	2,613,831	0	2,299,316	0	0	0	2,299,316	314,515
Adjustments in noncontrolling interest resulting from capital injections	0	0	513,397	0	0	0	513,397	(513,397)
Capital withdrawal by noncontrolling interest shareholders	(62,991,961)	0	(30,397,196)	0	0	1,014,074	(29,383,122)	(33,608,839)
Ordinary share issued in connection with:
Exercise of stock options	$ 3,558,796	$ 34	3,558,762	0	0	0	3,558,796	0
Exercise of stock options (in shares)	337,406	337,406
Vesting of restricted shares	$ 0	$ 25	(25)	0	0	0	0	0
Vesting of restricted shares (in shares)		255,150
Balance at Dec. 31, 2016	521,136,823	$ 2,943	105,459,610	(56,425,094)	438,483,401	(25,320,271)	462,200,589	58,936,234
Balance (in shares) at Dec. 31, 2016		29,427,609
Net income	82,235,959	$ 0	0	0	67,943,035	0	67,943,035	14,292,924
Other comprehensive income (loss)	36,861,394	0	0	0	0	33,277,575	33,277,575	3,583,819
Dividend declared to a noncontrolling interest shareholder	(10,680,008)	0	0	0	0	0	0	(10,680,008)
Share-based compensation	33,903,283		33,903,283	0	0	0	33,903,283	0
Ordinary share issued in connection with:
Exercise of stock options	$ 867,546	$ 9	867,537	0	0	0	867,546	0
Exercise of stock options (in shares)	85,242	85,242
Vesting of restricted shares	$ 0	$ 35	(35)	0	0	0	0	0
Vesting of restricted shares (in shares)		353,694
Balance at Dec. 31, 2017	664,324,997	$ 2,987	140,230,395	(56,425,094)	506,426,436	7,957,304	598,192,028	66,132,969
Balance (in shares) at Dec. 31, 2017		29,866,545
Net income	147,967,115	$ 0	0	0	128,056,302	0	128,056,302	19,910,813
Other comprehensive income (loss)	(60,783,829)	0	0	0	0	(53,668,005)	(53,668,005)	(7,115,824)
Dividend declared to a noncontrolling interest shareholder	(10,145,395)	0	0	0	0	0	0	(10,145,395)
Share-based compensation	23,130,570	0	23,130,570	0	0	0	23,130,570	0
Issuance of ordinary shares in private placement	590,265,000	$ 585	590,264,415	0	0	0	590,265,000	0
Issuance of ordinary shares in private placement (Shares)		5,850,000
Issuance of ordinary shares to PWM in exchange for 80% equity interest of TianXinFu	488,760,172	$ 552	434,888,618	0	0	0	434,889,170	53,871,002
Issuance of ordinary shares to PWM in exchange for 80% equity interest of TianXinFu (Shares)		5,521,000
Ordinary share issued in connection with:
Exercise of stock options	$ 1,184,534	$ 12	1,184,522	0	0	0	1,184,534	0
Exercise of stock options (in shares)	121,945	121,945
Vesting of restricted shares	$ 0	$ 26	(26)	0	0	0	0	0
Vesting of restricted shares (in shares)		256,830
Balance at Dec. 31, 2018	$ 1,844,703,164	$ 4,162	$ 1,189,698,494	$ (56,425,094)	$ 634,482,738	$ (45,710,701)	$ 1,722,049,599	$ 122,653,565
Balance (in shares) at Dec. 31, 2018		41,616,320

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 147,967,115	$ 82,235,959	$ 128,793,421
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	13,809,041	11,691,731	11,962,983
Amortization	9,416,310	1,216,959	775,053
Loss on disposal of property, plant and equipment	1,001,000	3,228,845	293,098
Allowance for doubtful accounts - accounts receivable, net	655,148	23,783	123,239
Allowance for doubtful accounts - prepayments and other receivables	96,267	0	65,341
Impairment for other non-current assets	2,671,528	0	1,225,200
Write-down of obsolete inventories	0	0	256,862
Deferred income tax benefit	(4,159,890)	(3,252,516)	(3,006,541)
Share-based compensation	23,130,570	33,903,283	24,405,511
Equity in income of an equity method investee	(2,368,995)	(3,509,071)	(2,519,201)
Loss from disposal of a subsidiary	0	0	75,891
Excess tax benefits from share-based compensation arrangements	0	0	(2,613,831)
Change in operating assets and liabilities, net of effect of acquisition of TianXinFu:
Accounts receivable	(53,879,876)	(39,918,939)	(10,971,773)
Inventories	(42,594,485)	(42,078,261)	(40,077,384)
Prepayments and other current assets	(9,387,783)	(1,777,783)	1,946,800
Accounts payable	8,140,553	977,152	2,966,885
Income tax payable	(3,575,544)	6,047,808	6,022,145
Other payables and accrued expenses	23,693,979	16,821,694	4,221,669
Deferred income	(504,886)	(493,897)	(686,757)
Non-current income tax payable	(10,168,100)	37,067,138	0
Net cash provided by operating activities	103,941,952	102,183,885	123,258,611
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash acquired from acquisition of TianXinFu	97,702,278	0	0
Purchase of time deposit	(1,871,773,012)	(22,669,000)	0
Proceeds from maturity of time deposit	1,349,949,821	0	0
Purchase of short term investments	(855,074,467)	0	0
Proceeds from maturity of short term investments	767,654,706	0	0
Payment for property, plant and equipment	(31,743,146)	(37,504,440)	(49,371,318)
Payment for intangible assets and land use rights	(4,973,244)	(786,691)	(1,635,891)
Refund of payments and deposits related to land use right	0	0	10,297,893
Proceeds from disposal of property, plant and equipment and land use rights	124,560	64,914	393,019
Loans lent to a third party	0	0	(12,332,718)
Proceeds from disposal of a subsidiary	0	0	128,654
Prepayments for investments in equity securities	(10,812,893)	0	0
Net cash used in investing activities	(558,945,397)	(60,895,217)	(52,520,361)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from stock option exercised	1,184,534	867,546	3,558,796
Proceeds from short-term bank loans	0	23,009,280	0
Repayment of short-term bank loans	0	(23,412,060)	0
Maturity of deposit as security for bank loans	0	0	37,756,405
Excess tax benefits from share-based compensation arrangements	0	0	2,613,831
Dividend paid by subsidiaries to noncontrolling interest shareholders	(10,145,395)	(18,789,151)	(7,921,952)
Proceeds from issuance of ordinary shares	590,265,000	0	0
Prepayment to an investment bank for potential share repurchase	(10,000,000)
Payment to noncontrolling interest shareholders in connection with their capital withdrawal	0	0	(58,091,018)
Net cash provided by/ (used in) financing activities	571,304,139	(18,324,385)	(22,083,938)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	3,243,017	12,607,032	(9,826,672)
NET INCREASE IN CASH AND CASH EQUIVALENTS	119,543,711	35,571,315	38,827,640
Cash and cash equivalents at beginning of year	219,336,848	183,765,533	144,937,893
Cash and cash equivalents at end of year	338,880,559	219,336,848	183,765,533
Supplemental cash flow information
Cash paid for income taxes	35,449,581	24,691,429	22,210,476
Cash paid for interest expense	0	252,353	84,664
Noncash investing and financing activities:
Acquisition of property, plant and equipment included in payables	3,687,742	7,548,964	4,912,937
Set-off loan receivable against accounts payable	3,784,297	0	5,848,400
Fair value of noncash assets acquired and liabilities assumed in acquisition of Tianxinfu	$ 337,186,892	$ 0	$ 0

DESCRIPTION OF BUSINESS AND SIG

DESCRIPTION OF BUSINESS AND SIGNIFICANT CONCENTRATIONS AND RISKS	12 Months Ended
	Dec. 31, 2018
Basis Of Presentation Significant Concentration and Risks [Abstract]
DESCRIPTION OF BUSINESS AND SIGNIFICANT CONCENTRATIONS AND RISKS	NOTE 1 – DESCRIPTION OF BUSINESS AND SIGNIFICANT CONCENTRATIONS AND RISKS China Biologic Products Holdings, Inc. (“CBP”) and its subsidiaries (collectively, the “Company”), are principally engaged in the research, development, manufacturing and sales of biopharmaceutical products in the People’s Republic of China (the “PRC”). Biopharmaceutical products include plasma-based products and placenta polypeptide. All of the biopharmaceutical products are prescription medicines administered in the form of injections. The principal plasma products are human albumin and human immunoglobulin for intravenous injection (“IVIG”). The PRC subsidiaries own and operate plasma collection stations that purchase and collect plasma from individual donors. The plasma is processed into finished goods after passing through a series of fractionating processes. On January 1, 2018, the Company acquired 80% equity interest in TianXinFu (Beijing) Medical Appliance Co., Ltd. (“TianXinFu”), a medical device company primarily engaging in manufacturing and sale of regenerative medical biomaterial products. Biomaterial products include artificial dura mater and spinal dura mater products, with extracted collagen as the main raw material, which are applied in brain and spinal surgeries. All of the Company’s plasma products require government approval before the products are sold to customers. The Company primarily sells its products to hospitals and inoculation centers directly or through distributors in the PRC. On July 21, 2017, China Biologic Products Holdings, Inc. (the “Successor”) succeeded to the interests of China Biologic Products, Inc. (the “Predecessor”) following a redomicile merger pursuant to an agreement and plan of merger dated as of April 28, 2017 (the “Merger Agreement”) between the Successor and the Predecessor. Pursuant to the Merger Agreement, the Predecessor merged with and into the Successor, with the Successor surviving the merger and each issued and outstanding shares of Predecessor's common stock converted into the right to receive one ordinary share of the Successor. The consolidated financial statements of the Successor represents the continuation of the financial statements of the Predecessor, reflecting the assets and liabilities, retained earnings and other equity balances of the Predecessor before the domiciliation. The equity structure is restated using the exchange ratio established in the Merger Agreement to reflect the number of shares of the Successor. Cash Concentration The Company maintains cash balances at financial institutions which, from time to time, may exceed Federal Deposit Insurance Corporation insured limits for its bank accounts located in the United States or may exceed Hong Kong Deposit Protection Board insured limits for its bank accounts located in Hong Kong or may exceed the insured limits for its bank accounts in China established by the People’s Bank of China. Total cash at banks and deposits, including cash and equivalents, time deposits and short term investments as of December 31, 2018 and December 31, 2017 amounted to $951,336,787 and $241,761,593, respectively, of which $3,227,530 and $2,577,139 are insured, respectively. The Company has not experienced any losses in uninsured bank deposits and does not believe that it is exposed to any significant risks on cash held in bank accounts. Sales Concentration The Company’s two major biopharmaceutical products are human albumin and IVIG. Human albumin accounted for 32.0%, 35.8% and 39.2% of the total sales for the years ended December 31, 2018, 2017 and 2016, respectively. IVIG accounted for 24.3%, 31.7% and 34.6% Substantially all of the Company’s customers are located in the PRC. There were no customers that individually comprised 10% or more of sales during the years ended December 31, 2018, 2017 and 2016. No individual customer represented 10% or more of accounts receivables as at December 31, 2018 and 2017. The Company performs ongoing credit evaluations of its customers’ financial condition and, generally, requires no collateral from its customers. Purchase Concentration There was one supplier, namely, Xinjiang Deyuan Bioengineering Co., Ltd. (“Xinjiang Deyuan”) (see Note 10), that comprised 10% or more of the total purchases during the years ended December 31, 2018, 2017 and 2016. No individual supplier represented 10% or more of accounts payables as at December 31, 2018. Chongqing Sanda Great Exploit Pharmaceutical Co, Ltd. represented more than 10% of accounts payables as at December 31, 2017.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation and Basis of Presentation The accompanying consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”), and include the financial statements of the Company and its subsidiaries in which CBP, directly or indirectly, has a controlling financial interest. All intercompany balances and transactions have been eliminated upon consolidation. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the useful lives of property, plant and equipment and intangibles with definite lives, the collectability of accounts receivable and loan receivable, the fair value determinations of stock compensation awards and short term investments, identifiable assets acquired and liabilities assumed and noncontrolling interest in business combinations, the realizability of deferred income tax assets and inventories, the recoverability of intangible assets, land use rights, property, plant and equipment, goodwill and equity method investment, and accruals for income tax uncertainties and other contingencies. The current economic environment has increased the degree of uncertainty inherent in those estimates and assumptions. Foreign Currency Translation The accompanying consolidated financial statements of the Company are reported in US dollar. The financial position and results of operations of the Company’s subsidiaries in the PRC are measured using the Renminbi, which is the local and functional currency of these entities. Assets and liabilities of the subsidiaries are translated at the prevailing exchange rate in effect at each period end. Revenues and expenses are translated at the average rate of exchange during the period. Translation adjustments are included in other comprehensive income/(losses). Revenue Recognition During the years ended December 31, 2017 and 2016, revenue was recognized when persuasive evidence of an arrangement existed, delivery of the product has occurred and the customer took ownership and assumed risk of loss, the sales price was fixed or determinable and collection of the relevant receivable was probable. For all sales, the Company required a signed contract or purchase order, which specified pricing, quantity and product specifications. Delivery of the product occurred when the customer received the product, which was when the risks and rewards of ownership have been transferred. Delivery was evidenced by signed customer acknowledgement. The Company’s sales agreements did not provide the customer the right of return, unless the product was defective in which case the Company allowed for an exchange of product or return. For the periods presented, defective product returns were inconsequential. Revenue represents the invoiced amount of products sold, net of value added taxes (VAT). Effective January 1, 2018, the Company adopted the new guidance of ASC Topic 606, Revenue from Contracts with Customers Revenue Recognition The Company sells biopharmaceutical and biomaterial products to hospitals, inoculation centers and distributors. For all sales, the Company requires a signed contract or purchase order, which specifies pricing, quantity and product specifications.The Company recognizes revenue upon the satisfaction of its performance obligation, which is to transfer the control of the promised products to customers in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for those products, excluding amounts collected on behalf of third parties (e.g. value-added taxes). The transfer of control of the products is satisfied at a point in time, which is the delivery of the products to customers’ premises and evidenced by signed customer acknowledgement. The selling price, which is specified in the signed contracts or purchase orders, is fixed. The Company has unconditional right to receive full payment of the sales price, upon the delivery of the products to customers and the signing of the customer acknowledgement. Customers are required to pay under the customary payment terms, which is generally less than six months. Advances from customers (a contract liability) is recognized when the Company has an unconditional right to a payment before it transfer the products to customers, and are included in other payables and accrued expenses. Fair Value Measurements The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: • Level 1 Inputs: Unadjusted quoted prices for identical assets or liabilities in active markets accessible to the entity at the measurement date. • Level 2 Inputs: Other than quoted prices included in Level 1, inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. • Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. The fair value measurement level of an asset or liability within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. See Note 15 to the Consolidated Financial Statements. Cash and Cash Equivalents Cash consists of cash on hand and demand deposits. The Company considers all highly liquid investments with original maturities of three-month or less at the time of purchase to be cash equivalents. As of December 31, 2018 and 2017, the Company maintained cash and cash equivalents at banks in the following locations: December 31, 2018 December 31, 2017 USD USD PRC, excluding Hong Kong 158,739,504 214,157,592 Hong Kong 3,936,815 - U.S. 175,133,834 4,708,801 Total 337,810,153 218,866,393 Short term investments The Company’s short term investments represent bank financial products with original maturity of less than one year when purchased. The Company elects to apply the fair value option for the short term investments to more accurately reflect market and economic events in its earnings. Gains or losses from the short term investments is recorded in other income, net in the statements of comprehensive income. Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable is recognized when the Company has an unconditional right to receive consideration. A right to receive consideration is unconditional if only the passage of time is required before payment of that consideration is due. Accounts receivable are recorded at the invoiced amount and do not bear interest. Amounts collected on trade accounts receivable are included in cash provided by operating activities in the consolidated statements of cash flows. The Company maintains an allowance for doubtful accounts for estimated losses inherent in its accounts receivable portfolio. In establishing the required allowance, management considers historical losses, the customers’ financial condition, the amount of accounts receivables in dispute, the accounts receivables aging and the customers’ payment patterns. The Company reviews its allowance for doubtful accounts monthly. Past due balances are reviewed individually for collectability. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company does not have any off-balance-sheet credit exposure related to its customers. Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined using the weighted average method. Cost of work-in-process and finished goods comprise direct materials, direct production costs and an allocation of production overheads based on normal operating capacity. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Adjustments are recorded to write down the carrying amount of any obsolete and excess inventory to its estimated net realizable value based on historical and forecasted demand. Property, Plant and Equipment Property, plant and equipment are stated at cost. Depreciation of property, plant and equipment attributable to manufacturing activities is capitalized as part of inventories, and recognized as cost of sales when the inventory is sold. Cost incurred in the construction of property, plant and equipment, including downpayments and progress payments, are initially capitalized as construction-in-progress and transferred into their respective asset categories when the assets are ready for their intended use, at which time depreciation commences. Depreciation on property, plant and equipment is calculated on the straight-line method over the estimated useful lives of the assets. Estimated useful lives of the assets are as follows: Buildings 20-45 years Machinery and equipment 10 years Furniture, fixtures, office equipment and vehicles 5-10 years When items are retired or otherwise disposed of, income is charged or credited for the difference between net book value and the proceeds received thereon. Ordinary maintenance and repairs are charged to expense as incurred, and replacements and betterments are capitalized and amortized over the remaining useful life. Business Combination The Company accounts for its business combination using the acquisition method in accordance with ASC Topic 805 (“ASC 805”): Business Combinations Goodwill Goodwill represents the excess of the aggregate purchase price over the fair value of identifiable assets acquired and liabilities assumed. Goodwill is not amortized, but is tested for impairment at the reporting unit level on at least an annual basis and more frequently when an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. When performing an evaluation of goodwill impairment, the Company has elected the option to first assess qualitative factors, such as significant events and changes to expectations and activities that may have occurred since the last impairment evaluation, to determine if it is more likely than not that goodwill might be impaired. If as a result of the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, the quantitative fair value test is performed to determine if the fair value of the reporting unit exceeds its carrying value. The Company has adopted Accounting Standards Update ("ASU") 2017-04, Simplifying the Test for Goodwill Impairment No impairment of goodwill was recognized for any of the years presented. Equity Method Investment Investment in an investee in which the Company has the ability to exercise significant influence, but does not have a controlling interest is accounted for using the equity method. Significant influence is generally presumed to exist when the Company has an ownership interest in the voting stock between 20% and 50 %, and other factors, such as representation on the board of directors and participation in policy-making processes, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the Company’s share of the investee’s results of operations is included in other income (expenses) in the Company’s consolidated statements of comprehensive income. Deferred taxes are provided for the difference, if any, between the book and tax basis of the investment. The Company determines the difference between the carrying amount of the investee and the underlying equity in net assets which results in an excess basis in the investment. The excess basis is allocated to the underlying assets and equity method goodwill of the Company’s investee. The excess basis allocated to the underlying assets is either amortized or depreciated over the applicable useful lives. The equity method goodwill, which is $1,192,320 and $1,252,387 at December 31, 2018 and 2017 , respectively, is not amortized or tested for impairment; instead the equity method investment is tested for impairment whenever events or changes in circumstances indicate that the carrying value of the investment may not be recoverable. The Company recognizes a loss if it is determined that other than temporary decline in the value of the investment exists. The process of assessing and determining whether an impairment on a particular equity investment is other than temporary requires significant amount of judgment. To determine whether an impairment is other-than-temporary, management considers whether the Company has the ability and intent to hold the investment until recovery and whether evidence indicating the carrying value of the investment is recoverable outweighs evidence to the contrary. No impairment loss was recognized by the Company the years ended December 31, 2018, 2017 and 2016. The Company’s equity method investment as of December 31, 2018 and 2017 represented 35% equity interest investment in Xi’an Huitian Blood Products Co., Ltd. (“Huitian”), which the Company acquired in October 2008. Government Grants Government grants are recognized when there is reasonable assurance that the Company will comply with the conditions attaching to them and the grants will be received. Grants that compensate research and development expenses are recognized as a reduction to the related research and development expenses. Grants that compensate the Company for the cost of property, plant and equipment and land use rights are recognized as deferred income and are recognized as a reduction of depreciation and amortization during the useful life of the asset. For the years ended December 31, 2018 4 ,837,300 (approximately $704,795), (approximately $ and (approximately $ , For the year ended December 31, 2012, the Company received government grants of RMB18,350,000 (approximately $2,989,215) related to the technical upgrade of the manufacturing facilities in Guizhou Taibang $277,801, $271,754 and $276,388 for the years ended December 31, 2018, 2017 and 2016, respectively. For the year ended December 31, 2015, the Company received government grants of RMB15,000,000 (approximately $2,452,864) related to the new manufacturing facilities for factor products in Shandong Taibang, which was recorded as deferred income. These grants are amortized as the related assets are depreciated. The grants amortized amounted to $227,085, $222,143 and $410,369 for the year ended December 31, 2018, 2017 and 2016, respectively. Intangible Assets Intangible assets with finite useful life are amortized on a straight-line basis, as the pattern of economic benefit of intangible assets cannot be reliably determined, over the estimated useful lives of the respective assets. The Company’s amortizable intangible assets consist of permits and license, customer relationships, technical know-how and others with the following estimated useful lives. Permits and license 5-10 years Customer relationships 7 years Technical know-how 3-12 years Others 5-10 years The estimated useful life is the period over which the intangible asset is expected to contribute directly or indirectly to the future cash flows of the Company. The in-process research and development assets acquired in a business combination are accounted for as an indefinite-lived intangible asset until completion or abandonment of the associated research and development activities. Land Use Rights Land use rights represent the exclusive right to occupy and use a piece of land in the PRC for a specified contractual term. Land use rights are carried at cost, less accumulated amortization. Amortization is calculated using the straight-line method over the contractual period of the rights ranging from 40 to 50 years. Research and Development Expenses Research and development costs are expensed as incurred. Research and development expenses for the years ended December 31, 2018, 2017 and 2016 were $9,524,412, $6,503,712 and $7,021,992, respectively. These expenses include the costs of the Company’s internal research and development activities. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax loss and tax credit carryforwards. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the consolidated statements of comprehensive income in the period that includes the enactment date. A valuation allowance is provided to reduce the amount of deferred income tax assets if it is considered more likely than not that some portion or all of the deferred income tax assets will not be realized. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expenses. Employee Benefit Plans Pursuant to relevant PRC regulations, the Company is required to make contributions to various defined contribution plans organized by municipal and provincial PRC governments. The contributions are made for each PRC employee at rates ranging from 25 The Company has no other obligation for the payment of employee benefits associated with these plans beyond the contributions described above. Share-based Payment The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award and recognizes the cost over the period the employee is required to provide service in exchange for the award, which generally is the vesting period. For graded vesting awards, the Company recognizes compensation cost on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date. Impairment of Long-lived Assets Long-lived assets, including property, plant and equipment, land use rights and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. Earnings per Share Basic earnings per ordinary share is computed by dividing net income attributable to ordinary shareholders by the weighted average number of ordinary share outstanding during the year using the two-class method. Under the two-class method, net income is allocated between ordinary share and other participating securities based on their participating rights in undistributed earnings. The Company’s nonvested shares were considered participating securities since the holders of these securities participate in dividends on the same basis as ordinary shareholders. Diluted earnings per share is calculated by dividing net income attributable to ordinary shareholders as adjusted for the effect of dilutive ordinary share equivalent, if any, by the weighted average number of ordinary share and dilutive ordinary share equivalent outstanding during the year. Potential dilutive securities are not included in the calculation of diluted earnings per share if the impact is anti-dilutive. Segment Reporting The Company uses the management approach in determining reportable operating segments. The management approach consider the internal reporting used by the chief operating decision maker for making operating decisions about the allocation of resources of the segment and the assessment of its performance in determining the Company’s reportable operating segments. As a result of the business combination completed on January 1, 2018 as described in Note 3, the Company classified the reportable operating segments for the year ended December 31, 2018 into (i) biopharmaceutical products and (ii) biomaterial products. Biopharmaceutical products currently include plasma products and placenta polypeptide. The Company had one operating segment, biopharmaceutical products segment, which included plasma-based products and placenta polypeptide for the years of 2017 and 2016. Substantially all of the Company’s operations and customers are located in the PRC, and therefore, no geographic information is presented. Contingencies In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations and tax matters. An accrual for a loss contingency is recognized when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Disclosure will be made if an unfavorable outcome is determined to be reasonably possible but not probable, or if the amount of loss cannot be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. Recently Issued Accounting Standards In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606) – Deferral of the Effective Date In July 2015, the FASB issued ASU No.2015-11, Simplifying the Measurement of Inventory (“ASU 2015-11”), which eliminated previous analysis of measurement of inventory and requires to measure most inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. ASU 2015-11 is effective prospectively for annual periods beginning after December 15, 2016, and interim periods therein. The Company adopted ASU 2015-11 on January 1, 2017 and concluded that no impact on its consolidated financial statements as a result of the new adoption of the guidance. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) Leases (Topic 842) : Targeted Improvements In August 2016 , the FASB issued ASU No. 2016 - 15 , Classification of Certain Cash Receipts and Cash Payments 2016 - 15 ”), which addressed and provided guidance for each of eight specific cash flow issues with the objective of reducing the existing diversity in practice. This standard will be effective for public companies for fiscal years beginning after December 15, 2017 , and interim periods within those fiscal years. The Company has early adopted ASU 2016 - 15 on its consolidated financial statements since January 1, 2017 and there was no impact as a result of the adoption. In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory This standard required that companies recognize the income tax consequences of an intra-entity transfer of an asset (other than inventory) when the transfer occurs. Current guidance prohibits companies from recognizing current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party. This standard will be effective for public companies for annual periods beginning after December 15, 2017, including interim periods within that reporting period. The Company has adopted ASU 2016-16 on its consolidated financial statements in 2017 and there was no impact as a result of the adoption. Effective January 1, 2017, on a retrospective basis, the Company adopted FASB ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes (Topic 740). This update required that deferred income tax assets and liabilities be classified as noncurrent. As a result of adoption of this guidance, the Company reclassified current deferred income tax assets in the amount of $4,625,996, which had been included in prepayments and other current assets, to other noncurrent assets as of December 31, 2016. There was no impact on results of operations or cash flows as a result of the adoption of this guidance. Effective January 1, 2017, the Company adopted FASB ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting . The standard simplified certain aspects of the accounting for share-based payment transactions, including recognition of excess tax benefits and deficiencies, classification of awards and classification in the statement of cash flows. As a result of adoption, the Company elected to adopt the change regarding income taxes on a prospective basis to recognize excess tax benefits and deficiencies from stock-based compensation as a discrete item in income tax expense, which were historically recorded as additional paid-in-capital. In addition, the Company elected to apply the change regarding classification in the statement of cash flows prospectively to record excess tax benefits from stock-based compensation from cash flows from financing activities to cash flows from operating activities. Excess tax benefits for the year ended December 31, 2017 was $621,381 and the adoption of this standard had no material impact on the Company’s financial statements. In January 2017, the FASB issued ASU No. 2017-01, Clarifying the Definition of a Business In January 2017, the FASB issued ASU No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment . In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13) .

BUSINESS COMBINATION

BUSINESS COMBINATION	12 Months Ended
	Dec. 31, 2018
Business Combination Disclosure [Abstract]
BUSINESS COMBINATION	NOTE 3 – BUSINESS COMBINATION On October 12, 2017, the Company entered into a definitive agreement with PW Medtech Group Limited (“PWM”), a company listed on the Stock Exchange of Hong Kong Limited, to acquire 80% equity interest of TianXinFu (Beijing) Medical Appliance Co., Ltd. (“TianXinFu”) in exchange for 5,521,000 ordinary shares of CBP. TianXinFu is a medical device company primarily engaging in the manufacturing and sale of regenerative medical biomaterial products, of which 80% equity interest was owned by PWM and 20% by a third party before this acquisition. The Company completed the acquisition on January 1, 2018. The transaction was accounted for under the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations The following table presents the amounts recognized for assets acquired and liabilities assumed for TianXinFu as of the acquisition date. The noncontrolling interest represents the fair value of the 20% equity interest not held by the Company: As of January 01, 2018 USD Cash and cash equivalents 97,702,278 Accounts receivable 312,832 Inventories 2,745,771 Other current assets 283,824 Property, plant and equipment 6,522,447 Land use rights 4,135,141 Intangible assets 63,725,856 Deferred income tax assets 480,334 Current liabilities (6,129,418 ) Deferred income tax liabilities (10,382,902 ) Fair value of noncontrolling interest (53,871,002 ) Goodwill 329,364,009 Total purchase consideration 434,889,170 The intangible assets consist of customer relationship, technical know-how and in-process research and development assets. The fair values of the customer relationship of $54,956,664 and technical know-how of $7,514,256 are amortized over 7 years and 3-12 years, respectively on a straight line basis. The fair value of in-process research and development assets of $1,254,937 are indefinite-lived until the completion or abandonment of the associated research and development activities. The estimated fair value of the noncontrolling interest in TianXinFu was determined by an independent valuer by using discount cash flow model. The goodwill resulting from the business combination primarily attributed to the synergies and economic scale anticipated to be achieved from combining the operations of the Company and TianXinFu, and the assigned assembled workforce. None of the goodwill is expected to be deductible for income tax purpose. As of the acquisition date, the goodwill acquired in the business combination was assigned to the biomaterial products segment of $182 million and to the biopharmaceutical products segment of $147 million. The exchange difference during the period for goodwill is $15,775,206. Unaudited Pro Forma Financial Information The following unaudited pro forma consolidated financial information for the year ended December 31, 2017 are presented as if the acquisition had been consummated on January 1, 2017 after giving effect to purchase accounting adjustments. These pro forma results have been prepared for comparative purpose only and do not purport to be indicative of what operating results would have been had the acquisition actually taken place on the date indicated and may not be indicative of future operating results. Unaudited pro forma consolidated statements of comprehensive income for the year ended December 31, 2017 : December 31, 2017 USD Sales 412,248,989 Net income 100,749,486

ACCOUNTS RECEIVABLE

ACCOUNTS RECEIVABLE	12 Months Ended
	Dec. 31, 2018
Accounts Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
ACCOUNTS RECEIVABLE	NOTE 4 – ACCOUNTS RECEIVABLE Accounts receivable at December 31, 2018 and 2017 consisted of the following: December 31, 2018 December 31, 2017 USD USD Accounts receivable 126,352,173 77,858,266 Less: Allowance for doubtful accounts (1,236,331 ) (590,991 ) Total 125,115,842 77,267,275 The activity in the allowance for doubtful accounts – accounts receivable for the years ended December 31, 2018, 2017 and 2016 are as follows: For the Years Ended December 31, 2018 December 31, 2017 December 31, 2016 USD USD USD Beginning balance 590,991 533,596 443,624 Provisions 655,148 23,783 123,239 Foreign currency translation adjustment (9,808 ) 33,612 (33,267 ) Ending balance 1,236,331 590,991 533,596

PREPAYMENTS AND OTHER CURRENT A

PREPAYMENTS AND OTHER CURRENT ASSETS	12 Months Ended
	Dec. 31, 2018
Prepaid And Other Current Asset [Abstract]
PREPAYMENTS AND OTHER CURRENT ASSETS	NOTE 5 – PREPAYMENTS AND OTHER CURRENT ASSETS Prepayments and other current assets as of December 31, 2018 mainly represented other receivables of $15,897,405, $9,081,680. 100 6 Prepayments and other current assets as of December 31, 2017 mainly represented other receivables of $10,412,739 and prepayments of $4,886,604. The activity in the allowance for doubtful accounts –prepayments and other receivables for the years ended December 31, 2018, 2017 and 2016 are as follows: For the Years Ended December 31, 2018 December 31, 2017 December 31, 2016 USD USD USD Beginning balance 4,960,020 4,671,896 4,924,063 Provisions 96,267 - 65,341 Foreign currency translation adjustment (273,194 ) 288,124 (317,508 ) Ending balance 4,783,093 4,960,020 4,671,896

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 6 – INVENTORIES Inventories at December 31, 2018 and 2017 consisted of the following: December 31, 2018 December 31, 2017 USD USD Raw materials 124,408,741 107,651,325 Work-in-process 57,457,153 42,202,306 Finished goods 61,429,618 59,717,204 Total 243,295,512 209,570,835 Raw materials mainly comprised of human plasma collected from the Company’s plasma collection stations. Work-in-process represented intermediate products in the process of production. Finished goods mainly comprised of plasma products. Provisions to write-down the carrying amount of obsolete inventory to its estimated net realizable value amounted to nil, nil and $256,862 for the years ended December 31, 2018, 2017 and 2016, respectively, and were recorded as cost of sales in the consolidated statements of comprehensive income.

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 7 – PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment at December 31, 2018 and 2017 consisted of the following: December 31, 2018 December 31, 2017 USD USD Buildings 86,923,161 41,669,081 Machinery and equipment 111,797,936 41,102,242 Furniture, fixtures, office equipment and vehicles 11,670,963 9,980,062 Construction in progress 7,713,523 105,226,787 Total property, plant and equipment, gross 218,105,583 197,978,172 Accumulated depreciation (42,447,406 ) (33,862,836 ) Impairment of property, plant and equipment (2,060,844 ) - Total property, plant and equipment, net 173,597,333 164,115,336 Prepayment for property, plant and equipment 4,730,028 2,697,413 Property, plant and equipment, net 178,327,361 166,812,749 As a result of the planned commencement of operation of the new facility, the Company disposed certain machinery and equipment in the old facility of Shandong Taibang and incurred a disposal loss of $ 1,001,000 3,228,845 Depreciation expense for the years ended December 31, 2018, 2017 and 2016 was $13,809,041, $11,691,731 and $11,962,983, respectively. No interest expenses were capitalized into construction in progress for the years ended December 31, 2018, 2017 and 2016.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 8 – INTANGIBLE ASSETS Intangible assets at December 31, 2018 and 2017 consisted of the following: December 31, 2018 December 31, 2017 USD USD Permits and license 4,579,081 4,809,764 Customer relationship 52,320,870 - Technical know-how 7,153,870 - In-process research and development assets 1,194,740 - Others 1,041,652 542,997 Total intangible assets 66,290,213 5,352,761 Accumulated amortization (13,031,342 ) (4,816,423 ) Total intangible assets, net 53,258,871 536,338 Amortization expense for the years ended December 31, 2018, 2017 and 2016 was $8,742,607, $497,344 and $570,288, respectively. The estimated annual amortization expense for intangible assets in each of the next five years is as follows: For the Years Ended December 31, Amount USD 2019 8,115,855 2020 8,108,251 2021 8,107,674 2022 8,103,936 2023 8,040,120 Total 40,475,836

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 9 – RELATED PARTY TRANSACTIONS Private Placement On August 24, 2018, the Company entered into (i) a share purchase agreement with Beachhead Holdings Limited (“Centurium”) and Double Double Holdings Limited (“DD”), which are affiliated with two directors of the Company, Mr. David Hui Li and Mr. Joseph Chow (ii) a share purchase agreement with PWM, the largest shareholder of the Company with a director representative, Ms. Yue’e Zhang (iii) share purchase agreements with two third party investors, for the issuance and sale of 3,050,000, 800,000 and 2,000,000 ordinary shares of 100.9 to raise aggregate gross proceeds of approximately $590 million. On the same date, CBP issued 1,800,000 ordinary shares to Centurium and 2,000,000 1,250,000 800,000 ordinary shares to PWM. Prepayments for Investments in Equity Securities On November 28, 2018, the Company entered into a share transfer agreement with Smart Step Investments Limited (“Smart Step”), the then largest shareholder of Beijing Taijie Weiye Technology Co., Ltd. (“TJWY Medical”), pursuant to which the Company purchased approximately 11.55% equity interests of TJWY Medical from Smart Step in a cash consideration of $10,812,893. Pursuant to the share transfer agreement, the Company has the right to request Smart Step to redeem full or part of the equity interests in TJWY transferred at the original purchase price plus 6% compound interest rate per annum. Such right can be exercised by the Company within 6 months from the third anniversary of the closing date of the transaction. The Company paid the 100% cash consideration on December 21, 2018. The transaction was completed on January 23, 2019. TJWY Medical is a manufacturer of interventional products. The ultimate beneficial owner of Smart Step is the mother of Ms. Yue’e Zhang, a director of the Company.

LOAN RECEIVABLE

LOAN RECEIVABLE	12 Months Ended
	Dec. 31, 2018
Loans Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
LOAN RECEIVABLE	NOTE 10 – LOAN RECEIVABLE In August 2015, the Company entered into a cooperation agreement with Xinjiang Deyuan and the controlling shareholder of Xinjiang Deyuan (“Deyuan Shareholder”). Pursuant to the agreement, (i) Xinjiang Deyuan agreed to sell to Guizhou Taibang no less than 500 tonnes of source plasma in batches over the next three years, before July 31, 2018, and (ii) Guizhou Taibang agreed to provide Xinjiang Deyuan with an interest-bearing loan at an interest rate of 6% per annum with an aggregate principal amount of RMB300,000,000 (approximately $43,710,000). The loan was due July 31, 2018 and secured by a pledge of Deyuan Shareholder’s 58.02% equity interest in Xinjiang Deyuan. In August 2018, the Company extended this cooperation agreement with Xinjiang Deyuan and Deyuan Shareholder for another 3 years to purchase at least an additional 500 tonnes of source plasma and to extend the due date of the loan to July 31, 2021.The loan is secured by a pledge of Deyuan Shareholder’s 58.02% equity interest in Xinjiang Deyuan. $3,784,297 of the loan principal was set off against the equivalent amount in accounts payable for purchase of plasma from Xinjiang Deyuan for the year ended December 31, 2018. Interest income of $2,904,886, $695,757, and $2,062,426,

OTHER PAYABLES AND ACCRUED EXPE

OTHER PAYABLES AND ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2018
Payables and Accruals [Abstract]
OTHER PAYABLES AND ACCRUED EXPENSES	NOTE 11 – OTHER PAYABLES AND ACCRUED EXPENSES Other payables and accrued expenses at December 31, 2018 and 2017 consisted of the following: December 31, 2018 December 31, 2017 USD USD Payables to a potential investor (1) 8,574,254 8,679,073 Payable to Guizhou Eakan Investing Corp. (2) 2,121,392 2,228,262 Salaries and bonuses payable 23,543,535 19,770,025 Accruals for sales promotion fee 29,401,827 19,346,659 Payables for construction work 8,181,773 9,135,810 Other tax payables 1,456,184 2,891,714 Advance from customers (3) 9,101,834 2,425,975 Deposits received 7,463,172 4,434,443 Others 10,089,822 6,915,903 Total 99,933,793 75,827,864 (1) The payables to a potential investor comprises deposits received from a potential investor in the amount of $4,977,112 and $5,227,846 as of December 31, 2018 and 2017, respectively, and related interest plus penalty on these deposits totaling $3,597,142 and $3,451,227 as of December 31, 2018 and 2017, respectively. (2) Guizhou Taibang has payables to Guizhou Eakan Investing Corp., amounting to approximately $2,121,392 and $2,228,262 as of December 31, 2018 and 2017, respectively. The Company borrowed this interest free advance for working capital purpose for Guizhou Taibang. The balance is due on demand. See Note 17. (3) The change in advance from customers primarily represents the cash received, less amounts recognized as sales during the year.

INCOME TAX

INCOME TAX	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
INCOME TAX	NOTE 12 – INCOME TAX The Company and each of its subsidiaries file separate income tax returns. The United States of America China Biologic Products Inc. was originally incorporated on December 20, 1989 under the laws of the State of Texas as Shepherd Food Equipment, Inc. On November 20, 2000, Shepherd Food Equipment, Inc. changed its corporate name to Shepherd Food Equipment, Inc. Acquisition Corp., or Shepherd. Shepherd is the survivor of a May 28, 2003 merger between Shepherd and GRC Holdings, Inc., or GRC, a Texas corporation. In the merger, the surviving corporation adopted the articles of incorporation and bylaws of GRC and changed its corporate name to GRC Holdings, Inc. On January 10, 2007, a plan of conversion became effective pursuant to which GRC was converted into a Delaware corporation and changed its name to China Biologic Products, Inc. With the completion of domiciliation to the Cayman Islands on July 21, 2017, China Biologic Products Inc. was merged with and into China Biologic Products Holdings, Inc., with China Biologic Products Holdings, Inc. as the surviving company. China Biologic Products Holdings, Inc. continued to be a U.S. corporation for U.S. federal income tax purposes and is subject to U.S. federal corporate income tax at gradual rates of up to 35% for year 2017. On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) was enacted. The Tax Act has made significant changes to the U.S. Internal Revenue Code, including the taxation of U.S. corporations, by, among other things, limiting interest deductions, reducing the U.S. corporate income tax rate, disallowing certain deductions that had previously been allowed, altering the expensing of capital expenditures, adopting elements of a territorial tax system, assessing a repatriation tax or “toll-charge” on undistributed earnings and profits of U.S.-owned foreign corporations, and introducing certain anti-base erosion provisions. In 2017, the Company recorded a charge of approximately $40.3 million as a provisional amount for the repatriation tax on deemed repatriation to the United States of accumulated earnings. The charge for deemed repatriation will be payable by the Company over an eight-year period commencing April 2018. In the second quarter of 2018, $3,250,000 repatriation tax was paid by the Company to the U.S. tax bureau. In August 2018, based on additional implementation guidance issued by the U.S. Treasury Department and the Internal Revenue Service, the Company adjusted the provisional amount by reversing income tax payable and income tax expense of $7.5 million. The accounting for the income tax effect of the Act has been completed. Cayman Islands Under the current laws of Cayman Islands, China Biologic Products Holdings, Inc. is not subject to tax on its income or capital gains. British Virgin Islands Taibang Biological is incorporated in the British Virgin Islands. Under the current laws of the British Virgin Islands (BVI), Taibang Biological is not subject to tax on income or capital gains. In addition, upon payments of dividends by Taibang Biological, no British Virgin Islands withholding tax is imposed. Hong Kong Taibang Holdings (Hong Kong) Limited (“Taibang Holdings”, formerly known as “Logic Holdings (Hong Kong) Limited”) is incorporated in Hong Kong and is subject to Hong Kong’s profits tax rate of 16.5% for the years ended December 31, 2018, 2017 and 2016. Taibang Holdings did not earn any income that was derived in Hong Kong for the years ended December 31, 2018, 2017 and 2016. Health Forward Holdings Limited (“Health Forward”) is incorporated in Hong Kong and is subject to Hong Kong’s profits tax rate of 16.5% for the year ended December 31, 2018. Health Forward did not earn any income that was derived in Hong Kong for the year ended December 31, 2018. The payments of dividends by Hong Kong companies are not subject to any Hong Kong withholding tax. PRC The PRC’s statutory income tax rate is 25%. The Company’s PRC subsidiaries are subject to income tax at 25% unless otherwise specified. In October 2014, Shandong Taibang obtained a notice from the Shandong provincial government that granted it the High and New Technology Enterprise certificate. This certificate entitled Shandong Taibang to enjoy a preferential income tax rate of 15% for a period of three years from 2014 to 2016. renewed its high and new technology enterprise qualification, which entitled it to enjoy a preferential income tax rate of 15% for a period of three years from 2017 to 2019. According to CaiShui [2011] No. 58 dated July 27, 2011, Guizhou Taibang, being a qualified enterprise located in the western region of the PRC, enjoys a preferential income tax rate of 15% effective retroactively from January 1, 2011 to December 31, 2020. TianXinFu was recognized by Beijing provincial government as a high and new technology enterprise in 2009 and the latest renewal of its qualification was obtained in 2018, which entitled TianXinFu to enjoy a preferential income tax rate of 15% for a period of three years from 2018 to 2020. The components of earnings (losses) before income tax expense by jurisdictions are as follows: For the Years Ended December 31, December 31, December 31, 2018 2017 2016 USD USD USD PRC, excluding Hong Kong 175,225,854 171,787,763 170,830,607 U.S. (11,303,223 ) (28,866,395 ) (19,408,283 ) BVI 2,341,136 3,488,680 2,498,629 Hong Kong (260,472 ) (2,280 ) (1,712 ) Total 166,003,295 146,407,768 153,919,241 Income tax expense for the years ended December 31, 2018, 2017 and 2016 represents current income tax expense and deferred income tax For the Years Ended December 31, December 31, December 31, 2018 2017 2016 USD USD USD Current income tax expense-PRC 29,715,744 27,133,958 28,132,361 Current income tax expense-US (7,519,674 ) 40,290,367 - Deferred income tax benefit-PRC (4,657,379 ) (3,252,516 ) (3,006,541 ) Deferred income tax expense-US 497,489 - - Total income tax expense 18,036,180 64,171,809 25,125,820 The effective income tax rate based on income tax expense and earnings before income taxes reported in the consolidated statements of comprehensive income differs from the PRC statutory income tax rate of 25% due to the following: For the Years Ended December 31, December 31, December 31, 2018 2017 2016 (in percentage to earnings before income tax expense) PRC statutory income tax rate 25.0 % 25.0 % 25.0 % Non-deductible expenses: Share-based compensation 1.4 % 3.7 % - Others 0.9 % 1.1 % 1.6 % Tax rate differential (0.5 )% (0.9 )% (3.6 )% Effect of PRC preferential tax rate (9.0 )% (11.1 )% (10.9 )% Bonus deduction on research and development expenses (2.3 )% (1.5 )% (1.5 )% Change in valuation allowance 0.4 % (0.6 )% 5.3 % Repatriation tax (4.5 )% 29.4 % - Tax effect of equity method investment 0.3 % (0.6 )% 0.4 % Excess tax benefits from stock option exercises (0.8 )% (0.7 )% - Effective income tax rate 10.9 % 43.8 % 16.3 % The PRC tax rate has been used because the majority of the Company’s consolidated pre-tax earnings arise in the PRC. As of December 31, 2018 and 2017, significant temporary differences between the tax basis and financial statement basis of assets and liabilities that gave rise to deferred taxes were principally related to the following: December 31, 2018 December 31, 2017 USD USD Deferred income tax assets arising from: -Accrued expenses 7,587,118 6,558,359 -Deferred income 213,086 258,255 -Property, Plant and Equipment 1,149,033 1,210,006 -Other non-current assets 158,607 146,918 -Tax loss carryforwards 4,300,813 5,031,657 Gross deferred income tax assets 13,408,657 13,205,195 Less: valuation allowance (4,300,813 ) (5,031,657 ) Net deferred income tax assets 9,107,844 8,173,538 Deferred income tax liabilities arising from: - Property, plant and equipment (129,636 ) - - Intangible assets (7,947,786 ) (148,467 ) - Land use rights (552,602 ) - - Equity method investment (497,489 ) - - Dividend withholding tax (3,774,778 ) (6,085,290 ) Deferred income tax liabilities (12,902,291 ) (6,233,757 ) Classification on consolidated balance sheets: Deferred income tax assets, included in other non-current assets 9,107,844 8,173,538 Deferred income tax liabilities, included in other liabilities (12,902,291 ) (6,233,757 ) In assessing the realizability of deferred income tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible and tax loss carryforwards are utilized. Management considers the scheduled reversal of deferred income tax liabilities (including the impact of available carryforwards periods), projected future taxable income, and tax planning strategies in making this assessment. The deferred income tax assets of $4,300,813 for tax loss carry forwards as of December 31, 2018 represented tax loss carryforwards of certain PRC subsidiaries. For PRC income tax purposes, these PRC subsidiaries had tax loss carryforwards of $18,526,347, of which $4,806,145, $4,204,366, $4,644,148, $728,172 and $4,143,516 would expire by 2019, 2020, 2021, 2022 and 2023, respectively, if unused. In view of their cumulative losses positions, management determined it is more likely than not that deferred income tax assets of these PRC subsidiaries will not be realized, and therefore full valuation allowances of $4,300,813 and $5,031,657 were provided as of December 31, 2018 and 2017, respectively. For United States federal income tax purposes, The following table presents the movement of the valuation allowance for deferred income tax assets for the years ended December 31, 2018, 2017 and 2016: For the Years Ended December 31, 2018 December 31, 2017 December 31, 2016 USD USD USD Beginning balance 5,031,657 26,629,179 8,160,611 Addition (deduction) during the year (507,897 ) (21,927,117 ) 18,676,456 Foreign currency translation adjustment (222,947 ) 329,595 (207,888 ) Ending balance 4,300,813 5,031,657 26,629,179 According to the prevailing PRC income tax law and relevant regulations, dividends relating to earnings accumulated beginning on January 1, 2008 that are received by non-PRC-resident enterprises from PRC-resident enterprises are subject to withholding tax at 10%, unless reduced by tax treaties or similar arrangement. Dividends relating to undistributed earnings generated prior to January 1, 2008 are exempt from such withholding tax. Further, dividends received by the Company from its overseas subsidiaries are subject to the U.S. federal income tax less any qualified foreign tax credits. Based on the dividend policy the Company has provided the deferred income tax liabilities of $7,351,023 on undistributed earnings of $74 million, approximately 50% of Shandong Taibang’s total undistributed earnings at December 31, 2014. During the years ended December 31, 2018, 2017 and 2016, the deferred income tax liabilities of $2,310,512, nil and $1,265,733 were paid following a sum of RMB148,760,000 (approximately $21,674,332), nil and RMB82,760,000 (approximately $11,929,854) dividend distribution to Taibang Holdings (Hong Kong) Limited by Taibang Biotech (Shandong) Co., Ltd. in 2018, 2017 and 2016, respectively, which was generated from distributed earnings of Shandong Taibang. Due to the Company’s plan and intention of reinvesting its earnings in its PRC business, the Company has not provided for the related deferred income tax liabilities on the remaining undistributed earnings of the PRC subsidiaries totaling $613.6 million as of December 31, 2018. As of January 1, 2016 and for each of the years ended December 31, 2018, 2017 and 2016, the Company and its subsidiaries did not have any unrecognized tax benefits, and therefore no interest or penalties related to unrecognized tax benefits were accrued. The Company does not expect that the amount of unrecognized tax benefits will change significantly within the next 12 months. The Company and each of its PRC subsidiaries file income tax returns in the United States and the PRC, respectively. The Company is subject to U.S. federal income tax examination by tax authorities for tax years beginning in 2007. According to the PRC Tax Administration and Collection Law, the statute of limitations is three years if the underpayment of taxes is due to computational errors made by the taxpayer or the withholding agent. The statute of limitations is extended to five years under special circumstances where the underpayment of taxes is more than RMB100,000 (approximately $14,570). In the case of transfer pricing issues, the statute of limitations is ten years. There is no statute of limitations in the case of tax evasion. The PRC tax returns for the Company’s PRC subsidiaries are open to examination by the PRC tax authorities for the tax years beginning in 2012.

OPTIONS AND NONVESTED SHARES

OPTIONS AND NONVESTED SHARES	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
OPTIONS AND NONVESTED SHARES	NOTE 13 – OPTIONS AND NONVESTED SHARES Options Effective May 9, 2008, the Board of Directors adopted the China Biologic 2008 Equity Incentive Plan, (“the 2008 Plan”). The 2008 Plan provides for grants of stock options, stock appreciation rights, performance units, restricted stock, restricted stock units and performance shares. A total of five million shares of the Company’s ordinary share may be issued pursuant to the 2008 Plan. The exercise price per share for the shares to be issued pursuant to an exercise of a stock option will be no less than the fair market value per share on the grant date, except that, in the case of an incentive stock option granted to a person who holds more than 10% of the total combined voting power of all classes of the Company’s stock or any of its subsidiaries, the exercise price will be no less than 110% of the fair market value per share on the grant date. All the options to be granted will have 10-year terms. The 2008 Plan expired on May 9, 2018 and all ordinary shares reserved under the 2008 Plan had been granted. For the years ended December 31, 2018, 2017 and 2016, no stock options to purchase ordinary share were granted to any directors or employees. A summary of stock options activity for the years ended December 31, 2018, 2017 and 2016 is as follows: Weighted Weighted Average Average Remaining Number of Exercise Contractual Aggregate Options Price Term in years Intrinsic Value USD USD Outstanding as of January 1, 2016 651,897 10.44 5.24 86,064,461 Granted - - Exercised (337,406 ) 10.55 (35,180,367 ) Forfeited and expired - - Outstanding as of December 31, 2016 314,491 10.32 3.84 30,568,083 Granted - - Exercised (85,242 ) 10.18 (7,868,258 ) Forfeited and expired - - Outstanding as of December 31, 2017 229,249 10.37 2.61 15,168,276 Granted - - Exercised (121,945 ) 9.71 (9,137,231 ) Forfeited and expired - - Outstanding as of December 31, 2018 107,304 11.13 2.28 7,570,681 Vested as of December 31, 2018 107,304 11.13 2.28 7,570,681 Exercisable as of December 31, 2018 107,304 11.13 2.28 7,570,681 For the years ended December 31, 2018, 2017 and 2016, the Company recorded stock compensation expense of nil, nil and $649,203, respectively, in general and administrative expenses. Nonvested shares For the years ended December 31, 2018, 2017 and 2016, nonvested shares were granted to certain directors and employees (collectively, the “Participant”). Pursuant to the nonvested share grant agreements between the Company and the Participant, the Participant will have all the rights of a shareholder with respect to the nonvested shares. The nonvested shares granted to directors generally vest in one or two years. The nonvested shares granted to employees generally vest in four years. A summary of nonvested shares activity for the year ended December 31, 2018, 2017 and 2016 is as follow: Number of Grant date weighted nonvested shares average fair value USD Outstanding as of January 1, 2016 669,100 77.49 Granted 511,200 119.75 Vested (255,150 ) 66.04 Forfeited (12,500 ) 66.74 Outstanding as of December 31, 2016 912,650 104.51 Granted 356,150 89.94 Vested (353,694 ) 91.32 Forfeited (1,080 ) 98.20 Outstanding as of December 31, 2017 914,026 103.95 Granted 333,620 79.23 Vested (256,830 ) 100.91 Forfeited (385,425 ) 98.86 Outstanding as of December 31, 2018 605,391 94.85 For the years ended December 31, 2018, 2017 and 2016, the Company recorded stock compensation expense of $23,130,570, $33,903,283 and $23,756,308 in general and administrative expenses, respectively. As of December 31, 2018, approximately $44,891,282 of stock compensation expense with respect to nonvested shares is to be recognized over weighted average period of approximately 2.32 years.

STATUTORY RESERVES

STATUTORY RESERVES	12 Months Ended
	Dec. 31, 2018
Statutory Accounting Practices [Abstract]
STATUTORY RESERVES	NOTE 14 – STATUTORY RESERVES The Company’s PRC subsidiaries are required to allocate at least 10% of its after tax profits as determined under generally accepted accounting principles in the PRC to its statutory surplus reserve until the reserve balance reaches 50% of respective registered capital. For the years ended December 31, 2018, 2017 and 2016, the Company's PRC subsidiaries made appropriations to the reserve fund of $18,844,626, $5,051 and $348,583, respectively. The accumulated balance of the statutory reserve as of December 31, 2018 and 2017 was $53,358,414 and $34,513,788, respectively.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 15 – FAIR VALUE MEASUREMENTS Financial assets and liabilities of the Company primarily comprise of cash and cash equivalents, time deposits, short term investments, accounts receivable, loan receivable-current, other receivables, loan receivable-non-current, accounts payable, and other payables and accrued expenses. Management used the following methods and assumptions to estimate the fair value of financial assets and liabilities at the relevant balance sheet dates: Fair Value of Financial Instruments Short-term financial assets and liabilities (including cash and cash equivalents, time deposits, accounts receivable, loan receivable-current, other receivables,accounts payable, and other payables and accrued expenses) – The carrying amounts of the short-term financial assets and liabilities approximate their fair values because of the short maturity of these instruments. Loan receivable-non-current – The carrying amounts of loan receivable approximate their fair value. The fair value is estimated using discounted cash flow analysis based on the borrower’s incremental borrowing rates for similar borrowing. Recurring Fair Value Measurements The Company elects the fair value option to account for short term investments. The Company values its short term investments using the effective interest method with inputs of annualized rate of return provided by issuing banks. The annualized rate of return may range from 3.00% to 4.65% depending on the amount and time period invested. The Company classifies the valuation techniques that use these inputs as Level 2.

SALES

SALES	12 Months Ended
	Dec. 31, 2018
Sales [Abstract]
SALES	NOTE 16 – SALES The Company’s sales by product categories for the years ended December 31, 2018, 2017 and 2016 are as follows: For the Years Ended December 31, December 31, December 31, USD USD USD Plasma products: Human Albumin 149,369,846 132,498,791 133,712,663 Immunoglobulin products: Human Immunoglobulin for Intravenous Injection 113,490,790 117,511,797 117,891,410 Other Immunoglobulin products 59,470,912 50,147,328 40,105,561 Others 31,677,439 21,049,636 17,281,111 Placenta Polypeptide 68,157,257 49,199,288 32,178,681 Biopharmaceutical products 422,166,244 370,406,840 341,169,426 Artificial Dura Mater 40,644,561 - - Others 4,066,764 - - Biomaterial products 44,711,325 - - Total 466,877,569 370,406,840 341,169,426 The Company’s sales by channel for the years ended December 31, 2018, 2017 and 2016 are as follows: For the Years Ended December 31, December 31, December 31, USD USD USD Plasma products: Distributors 174,698,620 126,381,596 120,297,097 Hospitals and inoculation centers 179,310,367 194,825,956 188,693,648 354,008,987 321,207,552 308,990,745 Placenta Polypeptide: Distributors 68,157,257 49,199,288 32,178,681 Total Biopharmaceutical products 422,166,244 370,406,840 341,169,426 Biomaterial products: Distributors 42,717,750 - - Hospitals 1,993,575 - - Total Biomaterial products 44,711,325 - - Total 466,877,569 370,406,840 341,169,426

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 17 – COMMITMENTS AND CONTINGENCIES Commitments As of December 31, 2018, commitments outstanding for operating lease approximated $ 2,129,052 As of December 31, 2018, commitments outstanding for the purchase of property, plant and equipment approximated $ 10,238,706 As of December 31, 2018, commitments outstanding for the purchase of plasma approximated $ 58,234,770 The following table sets forth the Company’s material contractual obligations as of December 31, 2018: Payments due by period Contractual Obligations Less than one year One to two years Two to three years Three to four years Four to five years Operating lease commitment 848,731 938,551 167,378 4,095 4,095 Purchase of plasma commitment (1) 14,018,867 27,925,833 16,290,070 - - Capital commitment 9,214,835 1,023,871 - - - Total 24,082,433 29,888,255 16,457,448 4,095 4,095 (1) See Note 10. Legal proceedings PRC Lawsuit In June 2017, an individual brought a lawsuit against Guizhou Taibang and Guizhou Eakan requesting repayment of RMB14,560,000 (approximately $2,121,392) and related fund possession cost amounting to approximately RMB37,141,600 (approximately $5,411,531). The plaintiff alleged that he entered into an agreement with Guizhou Eakan in May 2007, according to which he provided RMB14,560,000 for Guizhou Eakan to satisfy Guizhou Taibang’s loan request. On February 28, 2018, the trial was set in Shanghai Pudong New Area People’s Court. In March 2018, the court dismissed the trial for lack of jurisdiction and then transferred the trial to Shanghai No.1 Intermediate People's Court (“No.1 Court”). In January 2019, the No.1 Court held the trial and as of reporting date the ruling is still pending. The Company does not expect the plaintiff to prevail in this trial, but the Company cannot assure that the final outcome will be in favor of Guizhou Taibang. As of December 31, 2018, Guizhou Taibang has maintained RMB14,560,000 (approximately $2,121,392) payable to Guizhou Eakan on its balance sheet. Cayman Lawsuit On August 27, 2018, the Company’s former Chairman and CEO Mr. David (Xiaoying) Gao commenced a proceeding against the Company in the Grand Court of the Cayman Islands (the “Court”), principally seeking (a) a declaration that the private placement that was announced by the Company on August 24, 2018 was invalid and void, (b) an order requiring the Company to reverse and/or rescind any transactions carried out pursuant to the private placement, and (c) an injunction to prevent further shares from being issued by the Company to the entities participating in the private placement. The private placement was completed on September 21, 2018. On October 5, 2018, the Company made an application to the Court for dismissal of Mr. Gao’s lawsuit on the ground, among others, that Mr. Gao lacked standing to pursue the claims. On December 13, 2018, the Court granted the Company’s application and dismissed Mr. Gao’s lawsuit. On December 21, 2018, the Court granted Mr. Gao leave to appeal its December 13, 2018 order. Pursuant to the Cayman Islands Court of Appeal Rules, Mr. Gao was required to lodge a Notice of Appeal within 14 days of being granted leave to appeal. As of reporting date, the Company has not been served with a Notice of Appeal or any further documents relating to this litigation.

EARNINGS PER SHARE

EARNINGS PER SHARE	12 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Earnings per share	NOTE 18 – EARNINGS PER SHARE The following table sets forth the computation of basic and diluted earnings per share for the periods indicated: For the Years Ended December 31, December 31, December 31, 2018 2017 2016 USD USD USD Net income attributable to China Biologic Products Holdings, Inc. 128,056,302 67,943,035 104,779,307 Earnings allocated to participating nonvested shares (3,072,170 ) (2,188,633 ) (2,987,429 ) Net income used in basic and diluted earnings per ordinary share 124,984,132 65,754,402 101,791,878 Weighted average shares used in computing basic earnings per ordinary share 35,304,294 27,361,561 26,848,445 Diluted effect of stock option 128,665 244,062 400,699 Weighted average shares used in computing diluted earnings per ordinary share 35,432,959 27,605,623 27,249,144 Basic earnings per ordinary share 3.54 2.40 3.79 Diluted earnings per ordinary share 3.53 2.38 3.74 During the years ended December 31, 2018, 2017 and 2016, no potential ordinary shares outstanding were excluded from the calculation of diluted earnings per ordinary share.

CHINA BIOLOGIC PRODUCTS HOLDING

CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. (PARENT COMPANY)	12 Months Ended
	Dec. 31, 2018
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
CHINA BIOLOGIC PRODUCTS, INC. (PARENT COMPANY)	NOTE 19 – CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. (PARENT COMPANY) The following represents condensed unconsolidated financial information of the Parent Company only: Condensed Balance Sheets: December 31, 2018 December 31, 2017 USD USD Cash 175,133,834 4,708,801 Time deposits 430,000,000 3,000,000 Prepayments and prepaid expenses 12,140,443 87,070 Total Current Assets 617,274,277 7,795,871 Property, plant and equipment, net 88 145 Investment in and amounts due from subsidiaries 1,139,337,487 634,245,590 Total Assets 1,756,611,852 642,041,606 Other payables and accrued expenses 4,544,071 3,559,211 Income tax payable - current 2,621,655 3,223,229 Total Current Liabilities 7,165,726 6,782,440 Income tax payable - non current 26,899,038 37,067,138 Other liabilities 497,489 - Total Liabilities 34,562,253 43,849,578 Total Shareholders’ Equity 1,722,049,599 598,192,028 Total Liabilities and Shareholders’ Equity 1,756,611,852 642,041,606 Condensed Statements of Comprehensive Income: For the Years Ended December 31, 2018 December 31, 2017 December 31, 2016 USD USD USD Equity in income of subsidiaries 132,337,339 137,099,797 124,187,590 General and administrative expenses (16,575,019 ) (28,879,890 ) (19,408,283 ) Other income 5,271,797 13,495 - Earnings before income tax expense 121,034,117 108,233,402 104,779,307 Income tax (benefits)/expense (7,022,185 ) 40,290,367 - Net Income 128,056,302 67,943,035 104,779,307 Condensed Statements of Cash Flows: For the Years Ended December 31, 2018 December 31, 2017 December 31, 2016 USD USD USD Net cash used in operating activities (6,211,606 ) (3,830,330 ) (2,400,188 ) Net cash used in investing activities (404,812,895 ) (3,000,000 ) - Net cash provided by financing activities 581,449,534 - - Net increase (decrease) in cash 170,425,033 (6,830,330 ) (2,400,188 ) Cash at beginning of year 4,708,801 11,539,131 13,939,319 Cash at end of year 175,133,834 4,708,801 11,539,131

CAPITAL WITHDRAWAL BY TWO FORME

CAPITAL WITHDRAWAL BY TWO FORMER NONCONTROLLING INTEREST SHAREHOLDRERS OF GUIZHOU TAIBANG	12 Months Ended
	Dec. 31, 2018
Redeemable Noncontrolling Interest, Equity, Redemption Value [Abstract]
CAPITAL WITHDRAWAL BY TWO FORMER NONCONTROLLING INTEREST SHAREHOLDRERS OF GUIZHOU TAIBANG	NOTE 20 – CAPITAL WITHDRAWAL BY TWO FORMER NONCONTROLLING INTEREST SHAREHOLDRERS OF GUIZHOU TAIBANG On October 26, 2016, Guizhou Taibang completed the requisite legal and administrative procedures, through which two former minority shareholders, holding a combined 15.3% equity interest in Guizhou Taibang, withdrew their respective capital contributions in Guizhou Taibang for an aggregate consideration of RMB415,000,000 (approximately $58,091,018) pursuant to an agreement dated July 31, 2016.

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Dec. 31, 2018
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Segment Reporting Disclosure	NOTE 21 – SEGMENT INFORMATION The Company’s principal operating segments coincide with the types of products to be sold. The products from which revenues are derived are consistent with the reporting structure of the Company’s internal organization. The Company’s reportable segments for the year ended December 31, 2018 were biopharmaceutical products and biomaterial products as a result of the acquisition of completed on January 1, 2018 as described in Note 3. The Company had one operating segment, biopharmaceutical products segment, which included plasma-based products and placenta polypeptide for the years of 2017 and 2016. The Company’s chief operating decision-maker has been identified as the chief executive officer. There are no inter-segment revenue transactions and, therefore, revenues are only generated from external customers. The accounting policies of the segments are the same as those used by the Company. Segment information for the year ended and as of December 31, 2018 are as follows: Biopharmaceutical Products Biomaterial Products Total USD USD USD Year ended December 31, 2018 Sales 422,166,244 44,711,325 466,877,569 Cost of sales 141,683,089 5,104,147 146,787,236 Gross profit 280,483,155 39,607,178 320,090,333 Income from operations 128,980,355 17,192,396 146,172,751 Net income 131,561,108 16,406,007 147,967,115 Equity in income of an equity method investee 2,368,995 - 2,368,995 Interest income 13,704,954 1,796 13,706,750 Share-based compensation 23,130,570 - 23,130,570 Depreciation and Amortization 13,902,507 9,322,844 23,225,351 Income tax expense 15,353,208 2,682,972 18,036,180 Segment assets 2,095,996,321 348,885,628 2,444,881,949 Capital expenditures 35,245,016 1,471,374 36,716,390 Equity method investment 15,428,028 - 15,428,028 Reconciliation of segment assets to consolidated total assets: December 31, 2018 USD Year ended December 31, 2018 Total segment assets 2,444,881,949 Elimination of intercompany investment balances (434,903,268 ) Consolidated total assets 2,009,978,681 As substantially all of the Company's revenue is derived from the PRC and substantially all of the Company's long-lived assets are located in the PRC, no geographical information is presented. In addition, revenue derived from and long-lived assets located in Cayman Islands, the Company’s country of domicile, are immaterial.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 22 – SUBSEQUENT EVENTS PRC Legal Proceedings In January 2019, another individual who claimed to be a strategic investor of Guizhou Taibang brought a lawsuit against Guizhou Taibang, requesting to register her alleged ownership interest in Guizhou Taibang with the local Administration for Market Regulation (“AMR”, formerly known as the Administration of Industry and Commerce). The plaintiff alleged that she entered into an Equity Purchase Agreement with Guizhou Taibang in May 2007, according to which she paid RMB11,200,000 (approximately $1,631,840) to Guizhou Taibang in exchange for approximately 4.71% of Guizhou Taibang’s equity interests. The plaintiff and Guizhou Taibang are scheduled to exchange evidence on March 20, 2019. The Company does not expect the plaintiff to prevail in this trial, but the Company cannot assure that the final outcome will be in favor of Guizhou Taibang. Extension to Previously Announced Share Repurchase Program On March 4, 2019, the Board of Directors of the Company approved the extension to the Company’s previously authorized $100 million share repurchase program for another six months until October 31, 2019. The Company’s repurchases may be made from time to time on the open market at prevailing market prices, in negotiated transactions off the market, in block trades or through other legally permissible means. The timing and extent of any purchases will depend upon market conditions, the trading price of its shares and other factors, and are subject to the restrictions relating to volume, price and timing under applicable law.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation The accompanying consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”), and include the financial statements of the Company and its subsidiaries in which CBP, directly or indirectly, has a controlling financial interest. All intercompany balances and transactions have been eliminated upon consolidation.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the useful lives of property, plant and equipment and intangibles with definite lives, the collectability of accounts receivable and loan receivable, the fair value determinations of stock compensation awards and short term investments, identifiable assets acquired and liabilities assumed and noncontrolling interest in business combinations, the realizability of deferred income tax assets and inventories, the recoverability of intangible assets, land use rights, property, plant and equipment, goodwill and equity method investment, and accruals for income tax uncertainties and other contingencies. The current economic environment has increased the degree of uncertainty inherent in those estimates and assumptions.
Foreign Currency Translation	Foreign Currency Translation The accompanying consolidated financial statements of the Company are reported in US dollar. The financial position and results of operations of the Company’s subsidiaries in the PRC are measured using the Renminbi, which is the local and functional currency of these entities. Assets and liabilities of the subsidiaries are translated at the prevailing exchange rate in effect at each period end. Revenues and expenses are translated at the average rate of exchange during the period. Translation adjustments are included in other comprehensive income/(losses).
Revenue Recognition	Revenue Recognition During the years ended December 31, 2017 and 2016, revenue was recognized when persuasive evidence of an arrangement existed, delivery of the product has occurred and the customer took ownership and assumed risk of loss, the sales price was fixed or determinable and collection of the relevant receivable was probable. For all sales, the Company required a signed contract or purchase order, which specified pricing, quantity and product specifications. Delivery of the product occurred when the customer received the product, which was when the risks and rewards of ownership have been transferred. Delivery was evidenced by signed customer acknowledgement. The Company’s sales agreements did not provide the customer the right of return, unless the product was defective in which case the Company allowed for an exchange of product or return. For the periods presented, defective product returns were inconsequential. Revenue represents the invoiced amount of products sold, net of value added taxes (VAT). Effective January 1, 2018, the Company adopted the new guidance of ASC Topic 606, Revenue from Contracts with Customers Revenue Recognition The Company sells biopharmaceutical and biomaterial products to hospitals, inoculation centers and distributors. For all sales, the Company requires a signed contract or purchase order, which specifies pricing, quantity and product specifications.The Company recognizes revenue upon the satisfaction of its performance obligation, which is to transfer the control of the promised products to customers in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for those products, excluding amounts collected on behalf of third parties (e.g. value-added taxes). The transfer of control of the products is satisfied at a point in time, which is the delivery of the products to customers’ premises and evidenced by signed customer acknowledgement. The selling price, which is specified in the signed contracts or purchase orders, is fixed. The Company has unconditional right to receive full payment of the sales price, upon the delivery of the products to customers and the signing of the customer acknowledgement. Customers are required to pay under the customary payment terms, which is generally less than six months. Advances from customers (a contract liability) is recognized when the Company has an unconditional right to a payment before it transfer the products to customers, and are included in other payables and accrued expenses.
Fair Value Measurements	Fair Value Measurements The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: • Level 1 Inputs: Unadjusted quoted prices for identical assets or liabilities in active markets accessible to the entity at the measurement date. • Level 2 Inputs: Other than quoted prices included in Level 1, inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. • Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. The fair value measurement level of an asset or liability within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. See Note 15 to the Consolidated Financial Statements.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash consists of cash on hand and demand deposits. The Company considers all highly liquid investments with original maturities of three-month or less at the time of purchase to be cash equivalents. As of December 31, 2018 and 2017, the Company maintained cash and cash equivalents at banks in the following locations: December 31, 2018 December 31, 2017 USD USD PRC, excluding Hong Kong 158,739,504 214,157,592 Hong Kong 3,936,815 - U.S. 175,133,834 4,708,801 Total 337,810,153 218,866,393
Short term investments	Short term investments The Company’s short term investments represent bank financial products with original maturity of less than one year when purchased. The Company elects to apply the fair value option for the short term investments to more accurately reflect market and economic events in its earnings. Gains or losses from the short term investments is recorded in other income, net in the statements of comprehensive income.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable is recognized when the Company has an unconditional right to receive consideration. A right to receive consideration is unconditional if only the passage of time is required before payment of that consideration is due. Accounts receivable are recorded at the invoiced amount and do not bear interest. Amounts collected on trade accounts receivable are included in cash provided by operating activities in the consolidated statements of cash flows. The Company maintains an allowance for doubtful accounts for estimated losses inherent in its accounts receivable portfolio. In establishing the required allowance, management considers historical losses, the customers’ financial condition, the amount of accounts receivables in dispute, the accounts receivables aging and the customers’ payment patterns. The Company reviews its allowance for doubtful accounts monthly. Past due balances are reviewed individually for collectability. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company does not have any off-balance-sheet credit exposure related to its customers.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined using the weighted average method. Cost of work-in-process and finished goods comprise direct materials, direct production costs and an allocation of production overheads based on normal operating capacity. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Adjustments are recorded to write down the carrying amount of any obsolete and excess inventory to its estimated net realizable value based on historical and forecasted demand.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost. Depreciation of property, plant and equipment attributable to manufacturing activities is capitalized as part of inventories, and recognized as cost of sales when the inventory is sold. Cost incurred in the construction of property, plant and equipment, including downpayments and progress payments, are initially capitalized as construction-in-progress and transferred into their respective asset categories when the assets are ready for their intended use, at which time depreciation commences. Depreciation on property, plant and equipment is calculated on the straight-line method over the estimated useful lives of the assets. Estimated useful lives of the assets are as follows: Buildings 20-45 years Machinery and equipment 10 years Furniture, fixtures, office equipment and vehicles 5-10 years When items are retired or otherwise disposed of, income is charged or credited for the difference between net book value and the proceeds received thereon. Ordinary maintenance and repairs are charged to expense as incurred, and replacements and betterments are capitalized and amortized over the remaining useful life.
Business Combination	Business Combination The Company accounts for its business combination using the acquisition method in accordance with ASC Topic 805 (“ASC 805”): Business Combinations
Goodwill	Goodwill Goodwill represents the excess of the aggregate purchase price over the fair value of identifiable assets acquired and liabilities assumed. Goodwill is not amortized, but is tested for impairment at the reporting unit level on at least an annual basis and more frequently when an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. When performing an evaluation of goodwill impairment, the Company has elected the option to first assess qualitative factors, such as significant events and changes to expectations and activities that may have occurred since the last impairment evaluation, to determine if it is more likely than not that goodwill might be impaired. If as a result of the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, the quantitative fair value test is performed to determine if the fair value of the reporting unit exceeds its carrying value. The Company has adopted Accounting Standards Update ("ASU") 2017-04, Simplifying the Test for Goodwill Impairment No impairment of goodwill was recognized for any of the years presented.
Equity Method Investment	Equity Method Investment Investment in an investee in which the Company has the ability to exercise significant influence, but does not have a controlling interest is accounted for using the equity method. Significant influence is generally presumed to exist when the Company has an ownership interest in the voting stock between 20% and 50 %, and other factors, such as representation on the board of directors and participation in policy-making processes, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the Company’s share of the investee’s results of operations is included in other income (expenses) in the Company’s consolidated statements of comprehensive income. Deferred taxes are provided for the difference, if any, between the book and tax basis of the investment. The Company determines the difference between the carrying amount of the investee and the underlying equity in net assets which results in an excess basis in the investment. The excess basis is allocated to the underlying assets and equity method goodwill of the Company’s investee. The excess basis allocated to the underlying assets is either amortized or depreciated over the applicable useful lives. The equity method goodwill, which is $1,192,320 and $1,252,387 at December 31, 2018 and 2017 , respectively, is not amortized or tested for impairment; instead the equity method investment is tested for impairment whenever events or changes in circumstances indicate that the carrying value of the investment may not be recoverable. The Company recognizes a loss if it is determined that other than temporary decline in the value of the investment exists. The process of assessing and determining whether an impairment on a particular equity investment is other than temporary requires significant amount of judgment. To determine whether an impairment is other-than-temporary, management considers whether the Company has the ability and intent to hold the investment until recovery and whether evidence indicating the carrying value of the investment is recoverable outweighs evidence to the contrary. No impairment loss was recognized by the Company the years ended December 31, 2018, 2017 and 2016. The Company’s equity method investment as of December 31, 2018 and 2017 represented 35% equity interest investment in Xi’an Huitian Blood Products Co., Ltd. (“Huitian”), which the Company acquired in October 2008.
Government Grants	Government Grants Government grants are recognized when there is reasonable assurance that the Company will comply with the conditions attaching to them and the grants will be received. Grants that compensate research and development expenses are recognized as a reduction to the related research and development expenses. Grants that compensate the Company for the cost of property, plant and equipment and land use rights are recognized as deferred income and are recognized as a reduction of depreciation and amortization during the useful life of the asset. For the years ended December 31, 2018 4 ,837,300 (approximately $704,795), (approximately $ and (approximately $ , For the year ended December 31, 2012, the Company received government grants of RMB18,350,000 (approximately $2,989,215) related to the technical upgrade of the manufacturing facilities in Guizhou Taibang $277,801, $271,754 and $276,388 for the years ended December 31, 2018, 2017 and 2016, respectively. For the year ended December 31, 2015, the Company received government grants of RMB15,000,000 (approximately $2,452,864) related to the new manufacturing facilities for factor products in Shandong Taibang, which was recorded as deferred income. These grants are amortized as the related assets are depreciated. The grants amortized amounted to $227,085, $222,143 and $410,369 for the year ended December 31, 2018, 2017 and 2016, respectively.
Intangible assets	Intangible Assets Intangible assets with finite useful life are amortized on a straight-line basis, as the pattern of economic benefit of intangible assets cannot be reliably determined, over the estimated useful lives of the respective assets. The Company’s amortizable intangible assets consist of permits and license, customer relationships, technical know-how and others with the following estimated useful lives. Permits and license 5-10 years Customer relationships 7 years Technical know-how 3-12 years Others 5-10 years The estimated useful life is the period over which the intangible asset is expected to contribute directly or indirectly to the future cash flows of the Company. The in-process research and development assets acquired in a business combination are accounted for as an indefinite-lived intangible asset until completion or abandonment of the associated research and development activities.
Land Use Rights	Land Use Rights Land use rights represent the exclusive right to occupy and use a piece of land in the PRC for a specified contractual term. Land use rights are carried at cost, less accumulated amortization. Amortization is calculated using the straight-line method over the contractual period of the rights ranging from 40 to 50 years.
Research and Development Expenses	Research and Development Expenses Research and development costs are expensed as incurred. Research and development expenses for the years ended December 31, 2018, 2017 and 2016 were $9,524,412, $6,503,712 and $7,021,992, respectively. These expenses include the costs of the Company’s internal research and development activities.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax loss and tax credit carryforwards. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the consolidated statements of comprehensive income in the period that includes the enactment date. A valuation allowance is provided to reduce the amount of deferred income tax assets if it is considered more likely than not that some portion or all of the deferred income tax assets will not be realized. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expenses.
Employee Benefit Plans	Employee Benefit Plans Pursuant to relevant PRC regulations, the Company is required to make contributions to various defined contribution plans organized by municipal and provincial PRC governments. The contributions are made for each PRC employee at rates ranging from 25 The Company has no other obligation for the payment of employee benefits associated with these plans beyond the contributions described above.
Share-based Payment	Share-based Payment The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award and recognizes the cost over the period the employee is required to provide service in exchange for the award, which generally is the vesting period. For graded vesting awards, the Company recognizes compensation cost on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date.
Impairment of Long-lived Assets	Impairment of Long-lived Assets Long-lived assets, including property, plant and equipment, land use rights and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary.
Earnings per Share	Earnings per Share Basic earnings per ordinary share is computed by dividing net income attributable to ordinary shareholders by the weighted average number of ordinary share outstanding during the year using the two-class method. Under the two-class method, net income is allocated between ordinary share and other participating securities based on their participating rights in undistributed earnings. The Company’s nonvested shares were considered participating securities since the holders of these securities participate in dividends on the same basis as ordinary shareholders. Diluted earnings per share is calculated by dividing net income attributable to ordinary shareholders as adjusted for the effect of dilutive ordinary share equivalent, if any, by the weighted average number of ordinary share and dilutive ordinary share equivalent outstanding during the year. Potential dilutive securities are not included in the calculation of diluted earnings per share if the impact is anti-dilutive.
Segment Reporting	Segment Reporting The Company uses the management approach in determining reportable operating segments. The management approach consider the internal reporting used by the chief operating decision maker for making operating decisions about the allocation of resources of the segment and the assessment of its performance in determining the Company’s reportable operating segments. As a result of the business combination completed on January 1, 2018 as described in Note 3, the Company classified the reportable operating segments for the year ended December 31, 2018 into (i) biopharmaceutical products and (ii) biomaterial products. Biopharmaceutical products currently include plasma products and placenta polypeptide. The Company had one operating segment, biopharmaceutical products segment, which included plasma-based products and placenta polypeptide for the years of 2017 and 2016. Substantially all of the Company’s operations and customers are located in the PRC, and therefore, no geographic information is presented.
Contingencies	Contingencies In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations and tax matters. An accrual for a loss contingency is recognized when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Disclosure will be made if an unfavorable outcome is determined to be reasonably possible but not probable, or if the amount of loss cannot be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.
Recently Issued Accounting Standards	Recently Issued Accounting Standards In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606) – Deferral of the Effective Date In July 2015, the FASB issued ASU No.2015-11, Simplifying the Measurement of Inventory (“ASU 2015-11”), which eliminated previous analysis of measurement of inventory and requires to measure most inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. ASU 2015-11 is effective prospectively for annual periods beginning after December 15, 2016, and interim periods therein. The Company adopted ASU 2015-11 on January 1, 2017 and concluded that no impact on its consolidated financial statements as a result of the new adoption of the guidance. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) Leases (Topic 842) : Targeted Improvements In August 2016 , the FASB issued ASU No. 2016 - 15 , Classification of Certain Cash Receipts and Cash Payments 2016 - 15 ”), which addressed and provided guidance for each of eight specific cash flow issues with the objective of reducing the existing diversity in practice. This standard will be effective for public companies for fiscal years beginning after December 15, 2017 , and interim periods within those fiscal years. The Company has early adopted ASU 2016 - 15 on its consolidated financial statements since January 1, 2017 and there was no impact as a result of the adoption. In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory This standard required that companies recognize the income tax consequences of an intra-entity transfer of an asset (other than inventory) when the transfer occurs. Current guidance prohibits companies from recognizing current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party. This standard will be effective for public companies for annual periods beginning after December 15, 2017, including interim periods within that reporting period. The Company has adopted ASU 2016-16 on its consolidated financial statements in 2017 and there was no impact as a result of the adoption. Effective January 1, 2017, on a retrospective basis, the Company adopted FASB ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes (Topic 740). This update required that deferred income tax assets and liabilities be classified as noncurrent. As a result of adoption of this guidance, the Company reclassified current deferred income tax assets in the amount of $4,625,996, which had been included in prepayments and other current assets, to other noncurrent assets as of December 31, 2016. There was no impact on results of operations or cash flows as a result of the adoption of this guidance. Effective January 1, 2017, the Company adopted FASB ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting . The standard simplified certain aspects of the accounting for share-based payment transactions, including recognition of excess tax benefits and deficiencies, classification of awards and classification in the statement of cash flows. As a result of adoption, the Company elected to adopt the change regarding income taxes on a prospective basis to recognize excess tax benefits and deficiencies from stock-based compensation as a discrete item in income tax expense, which were historically recorded as additional paid-in-capital. In addition, the Company elected to apply the change regarding classification in the statement of cash flows prospectively to record excess tax benefits from stock-based compensation from cash flows from financing activities to cash flows from operating activities. Excess tax benefits for the year ended December 31, 2017 was $621,381 and the adoption of this standard had no material impact on the Company’s financial statements. In January 2017, the FASB issued ASU No. 2017-01, Clarifying the Definition of a Business In January 2017, the FASB issued ASU No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment . In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13) .

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule of cash at banks	As of December 31, 2018 and 2017, the Company maintained cash and cash equivalents at banks in the following locations: December 31, 2018 December 31, 2017 USD USD PRC, excluding Hong Kong 158,739,504 214,157,592 Hong Kong 3,936,815 - U.S. 175,133,834 4,708,801 Total 337,810,153 218,866,393
Schedule of estimated useful lives of property, plant and equipment	Depreciation on property, plant and equipment is calculated on the straight-line method over the estimated useful lives of the assets. Estimated useful lives of the assets are as follows: Buildings 20-45 years Machinery and equipment 10 years Furniture, fixtures, office equipment and vehicles 5-10 years
Schedule of estimated useful lives of intangible assets	Permits and license 5-10 years Customer relationships 7 years Technical know-how 3-12 years Others 5-10 years

BUSINESS COMBINATION (Tables)

BUSINESS COMBINATION (Tables)	12 Months Ended
	Dec. 31, 2018
Business Combination Disclosure [Abstract]
Schedule of Business Acquisitions, by Acquisition	The following table presents the amounts recognized for assets acquired and liabilities assumed for TianXinFu as of the acquisition date. The noncontrolling interest represents the fair value of the 20% equity interest not held by the Company: As of January 01, 2018 USD Cash and cash equivalents 97,702,278 Accounts receivable 312,832 Inventories 2,745,771 Other current assets 283,824 Property, plant and equipment 6,522,447 Land use rights 4,135,141 Intangible assets 63,725,856 Deferred income tax assets 480,334 Current liabilities (6,129,418 ) Deferred income tax liabilities (10,382,902 ) Fair value of noncontrolling interest (53,871,002 ) Goodwill 329,364,009 Total purchase consideration 434,889,170
Business Acquisition, Pro Forma Information	Unaudited pro forma consolidated statements of comprehensive income for the year ended December 31, 2017 : December 31, 2017 USD Sales 412,248,989 Net income 100,749,486

ACCOUNTS RECEIVABLE (Tables)

ACCOUNTS RECEIVABLE (Tables)	12 Months Ended
	Dec. 31, 2018
SCHEDULE OF ACCOUNTS RECEIVABLE	Accounts receivable at December 31, 2018 and 2017 consisted of the following: December 31, 2018 December 31, 2017 USD USD Accounts receivable 126,352,173 77,858,266 Less: Allowance for doubtful accounts (1,236,331 ) (590,991 ) Total 125,115,842 77,267,275
Accounts Receivable [Member]
SCHEDULE OF ACTIVITIES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS	The activity in the allowance for doubtful accounts – accounts receivable for the years ended December 31, 2018, 2017 and 2016 are as follows: For the Years Ended December 31, 2018 December 31, 2017 December 31, 2016 USD USD USD Beginning balance 590,991 533,596 443,624 Provisions 655,148 23,783 123,239 Foreign currency translation adjustment (9,808 ) 33,612 (33,267 ) Ending balance 1,236,331 590,991 533,596

PREPAYMENTS AND OTHER CURRENT_2

PREPAYMENTS AND OTHER CURRENT ASSETS (Tables)	12 Months Ended
	Dec. 31, 2018
Other Receivables And Prepayments [Member]
Prepayments And Other Current Assets [Line Items]
SCHEDULE OF ACTIVITIES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS	The activity in the allowance for doubtful accounts –prepayments and other receivables for the years ended December 31, 2018, 2017 and 2016 are as follows: For the Years Ended December 31, 2018 December 31, 2017 December 31, 2016 USD USD USD Beginning balance 4,960,020 4,671,896 4,924,063 Provisions 96,267 - 65,341 Foreign currency translation adjustment (273,194 ) 288,124 (317,508 ) Ending balance 4,783,093 4,960,020 4,671,896

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
SCHEDULE OF INVENTORIES	Inventories at December 31, 2018 and 2017 consisted of the following: December 31, 2018 December 31, 2017 USD USD Raw materials 124,408,741 107,651,325 Work-in-process 57,457,153 42,202,306 Finished goods 61,429,618 59,717,204 Total 243,295,512 209,570,835

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT	Property, plant and equipment at December 31, 2018 and 2017 consisted of the following: December 31, 2018 December 31, 2017 USD USD Buildings 86,923,161 41,669,081 Machinery and equipment 111,797,936 41,102,242 Furniture, fixtures, office equipment and vehicles 11,670,963 9,980,062 Construction in progress 7,713,523 105,226,787 Total property, plant and equipment, gross 218,105,583 197,978,172 Accumulated depreciation (42,447,406 ) (33,862,836 ) Impairment of property, plant and equipment (2,060,844 ) - Total property, plant and equipment, net 173,597,333 164,115,336 Prepayment for property, plant and equipment 4,730,028 2,697,413 Property, plant and equipment, net 178,327,361 166,812,749

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Intangible assets at December 31, 2018 and 2017 consisted of the following: December 31, 2018 December 31, 2017 USD USD Permits and license 4,579,081 4,809,764 Customer relationship 52,320,870 - Technical know-how 7,153,870 - In-process research and development assets 1,194,740 - Others 1,041,652 542,997 Total intangible assets 66,290,213 5,352,761 Accumulated amortization (13,031,342 ) (4,816,423 ) Total intangible assets, net 53,258,871 536,338
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The estimated annual amortization expense for intangible assets in each of the next five years is as follows: For the Years Ended December 31, Amount USD 2019 8,115,855 2020 8,108,251 2021 8,107,674 2022 8,103,936 2023 8,040,120 Total 40,475,836

OTHER PAYABLES AND ACCRUED EX_2

OTHER PAYABLES AND ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2018
Payables and Accruals [Abstract]
SCHEDULE OF OTHER PAYABLES AND ACCRUED EXPENSES	Other payables and accrued expenses at December 31, 2018 and 2017 consisted of the following: December 31, 2018 December 31, 2017 USD USD Payables to a potential investor (1) 8,574,254 8,679,073 Payable to Guizhou Eakan Investing Corp. (2) 2,121,392 2,228,262 Salaries and bonuses payable 23,543,535 19,770,025 Accruals for sales promotion fee 29,401,827 19,346,659 Payables for construction work 8,181,773 9,135,810 Other tax payables 1,456,184 2,891,714 Advance from customers (3) 9,101,834 2,425,975 Deposits received 7,463,172 4,434,443 Others 10,089,822 6,915,903 Total 99,933,793 75,827,864 (1) The payables to a potential investor comprises deposits received from a potential investor in the amount of $4,977,112 and $5,227,846 as of December 31, 2018 and 2017, respectively, and related interest plus penalty on these deposits totaling $3,597,142 and $3,451,227 as of December 31, 2018 and 2017, respectively. (2) Guizhou Taibang has payables to Guizhou Eakan Investing Corp., amounting to approximately $2,121,392 and $2,228,262 as of December 31, 2018 and 2017, respectively. The Company borrowed this interest free advance for working capital purpose for Guizhou Taibang. The balance is due on demand. See Note 17. (3) The change in advance from customers primarily represents the cash received, less amounts recognized as sales during the year.

INCOME TAX (Tables)

INCOME TAX (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
SCHEDULE OF EARNINGS (LOSSES) BEFORE INCOME TAXES BY JURISDICTIONS	The components of earnings (losses) before income tax expense by jurisdictions are as follows: For the Years Ended December 31, December 31, December 31, 2018 2017 2016 USD USD USD PRC, excluding Hong Kong 175,225,854 171,787,763 170,830,607 U.S. (11,303,223 ) (28,866,395 ) (19,408,283 ) BVI 2,341,136 3,488,680 2,498,629 Hong Kong (260,472 ) (2,280 ) (1,712 ) Total 166,003,295 146,407,768 153,919,241
SCHEDULE OF INCOME TAX EXPENSE	Income tax expense for the years ended December 31, 2018, 2017 and 2016 represents current income tax expense and deferred income tax For the Years Ended December 31, December 31, December 31, 2018 2017 2016 USD USD USD Current income tax expense-PRC 29,715,744 27,133,958 28,132,361 Current income tax expense-US (7,519,674 ) 40,290,367 - Deferred income tax benefit-PRC (4,657,379 ) (3,252,516 ) (3,006,541 ) Deferred income tax expense-US 497,489 - - Total income tax expense 18,036,180 64,171,809 25,125,820
SCHEDULE OF RECONCILIATION OF INCOME TAX EXPENSE	The effective income tax rate based on income tax expense and earnings before income taxes reported in the consolidated statements of comprehensive income differs from the PRC statutory income tax rate of 25% due to the following: For the Years Ended December 31, December 31, December 31, 2018 2017 2016 (in percentage to earnings before income tax expense) PRC statutory income tax rate 25.0 % 25.0 % 25.0 % Non-deductible expenses: Share-based compensation 1.4 % 3.7 % - Others 0.9 % 1.1 % 1.6 % Tax rate differential (0.5 )% (0.9 )% (3.6 )% Effect of PRC preferential tax rate (9.0 )% (11.1 )% (10.9 )% Bonus deduction on research and development expenses (2.3 )% (1.5 )% (1.5 )% Change in valuation allowance 0.4 % (0.6 )% 5.3 % Repatriation tax (4.5 )% 29.4 % - Tax effect of equity method investment 0.3 % (0.6 )% 0.4 % Excess tax benefits from stock option exercises (0.8 )% (0.7 )% - Effective income tax rate 10.9 % 43.8 % 16.3 %
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES	As of December 31, 2018 and 2017, significant temporary differences between the tax basis and financial statement basis of assets and liabilities that gave rise to deferred taxes were principally related to the following: December 31, 2018 December 31, 2017 USD USD Deferred income tax assets arising from: -Accrued expenses 7,587,118 6,558,359 -Deferred income 213,086 258,255 -Property, Plant and Equipment 1,149,033 1,210,006 -Other non-current assets 158,607 146,918 -Tax loss carryforwards 4,300,813 5,031,657 Gross deferred income tax assets 13,408,657 13,205,195 Less: valuation allowance (4,300,813 ) (5,031,657 ) Net deferred income tax assets 9,107,844 8,173,538 Deferred income tax liabilities arising from: - Property, plant and equipment (129,636 ) - - Intangible assets (7,947,786 ) (148,467 ) - Land use rights (552,602 ) - - Equity method investment (497,489 ) - - Dividend withholding tax (3,774,778 ) (6,085,290 ) Deferred income tax liabilities (12,902,291 ) (6,233,757 ) Classification on consolidated balance sheets: Deferred income tax assets, included in other non-current assets 9,107,844 8,173,538 Deferred income tax liabilities, included in other liabilities (12,902,291 ) (6,233,757 )
SUMMARY OF VALUATION ALLOWANCE FOR DEFERRED TAX ASSETS	The following table presents the movement of the valuation allowance for deferred income tax assets for the years ended December 31, 2018, 2017 and 2016: For the Years Ended December 31, 2018 December 31, 2017 December 31, 2016 USD USD USD Beginning balance 5,031,657 26,629,179 8,160,611 Addition (deduction) during the year (507,897 ) (21,927,117 ) 18,676,456 Foreign currency translation adjustment (222,947 ) 329,595 (207,888 ) Ending balance 4,300,813 5,031,657 26,629,179

OPTIONS AND NONVESTED SHARES (T

OPTIONS AND NONVESTED SHARES (Tables)	12 Months Ended
	Dec. 31, 2018
Options and Nonvested Shares [Abstract]
SCHEDULE OF STOCK OPTIONS ACTIVITY	A summary of stock options activity for the years ended December 31, 2018, 2017 and 2016 is as follows: Weighted Weighted Average Average Remaining Number of Exercise Contractual Aggregate Options Price Term in years Intrinsic Value USD USD Outstanding as of January 1, 2016 651,897 10.44 5.24 86,064,461 Granted - - Exercised (337,406 ) 10.55 (35,180,367 ) Forfeited and expired - - Outstanding as of December 31, 2016 314,491 10.32 3.84 30,568,083 Granted - - Exercised (85,242 ) 10.18 (7,868,258 ) Forfeited and expired - - Outstanding as of December 31, 2017 229,249 10.37 2.61 15,168,276 Granted - - Exercised (121,945 ) 9.71 (9,137,231 ) Forfeited and expired - - Outstanding as of December 31, 2018 107,304 11.13 2.28 7,570,681 Vested as of December 31, 2018 107,304 11.13 2.28 7,570,681 Exercisable as of December 31, 2018 107,304 11.13 2.28 7,570,681
SCHEDULE OF NONVESTED SHARES ACTIVITY	A summary of nonvested shares activity for the year ended December 31, 2018, 2017 and 2016 is as follow: Number of Grant date weighted nonvested shares average fair value USD Outstanding as of January 1, 2016 669,100 77.49 Granted 511,200 119.75 Vested (255,150 ) 66.04 Forfeited (12,500 ) 66.74 Outstanding as of December 31, 2016 912,650 104.51 Granted 356,150 89.94 Vested (353,694 ) 91.32 Forfeited (1,080 ) 98.20 Outstanding as of December 31, 2017 914,026 103.95 Granted 333,620 79.23 Vested (256,830 ) 100.91 Forfeited (385,425 ) 98.86 Outstanding as of December 31, 2018 605,391 94.85

SALES (Tables)

SALES (Tables)	12 Months Ended
	Dec. 31, 2018
Sales Disclosure [Abstract]
SCHEDULE OF SALES BY PRODUCT TYPE	The Company’s sales by product categories for the years ended December 31, 2018, 2017 and 2016 are as follows: For the Years Ended December 31, December 31, December 31, USD USD USD Plasma products: Human Albumin 149,369,846 132,498,791 133,712,663 Immunoglobulin products: Human Immunoglobulin for Intravenous Injection 113,490,790 117,511,797 117,891,410 Other Immunoglobulin products 59,470,912 50,147,328 40,105,561 Others 31,677,439 21,049,636 17,281,111 Placenta Polypeptide 68,157,257 49,199,288 32,178,681 Biopharmaceutical products 422,166,244 370,406,840 341,169,426 Artificial Dura Mater 40,644,561 - - Others 4,066,764 - - Biomaterial products 44,711,325 - - Total 466,877,569 370,406,840 341,169,426
Schedule Of Revenue From Products [Table Text Block]	The Company’s sales by channel for the years ended December 31, 2018, 2017 and 2016 are as follows: For the Years Ended December 31, December 31, December 31, USD USD USD Plasma products: Distributors 174,698,620 126,381,596 120,297,097 Hospitals and inoculation centers 179,310,367 194,825,956 188,693,648 354,008,987 321,207,552 308,990,745 Placenta Polypeptide: Distributors 68,157,257 49,199,288 32,178,681 Total Biopharmaceutical products 422,166,244 370,406,840 341,169,426 Biomaterial products: Distributors 42,717,750 - - Hospitals 1,993,575 - - Total Biomaterial products 44,711,325 - - Total 466,877,569 370,406,840 341,169,426

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Contractual Obligation, Fiscal Year Maturity Schedule	The following table sets forth the Company’s material contractual obligations as of December 31, 2018: Payments due by period Contractual Obligations Less than one year One to two years Two to three years Three to four years Four to five years Operating lease commitment 848,731 938,551 167,378 4,095 4,095 Purchase of plasma commitment (1) 14,018,867 27,925,833 16,290,070 - - Capital commitment 9,214,835 1,023,871 - - - Total 24,082,433 29,888,255 16,457,448 4,095 4,095 (1) See Note 10.

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2018
Net Income Loss Per Share Disclosure [Abstract]
SCHEDULE OF EPS - BASIC AND DILUTED	The following table sets forth the computation of basic and diluted earnings per share for the periods indicated: For the Years Ended December 31, December 31, December 31, 2018 2017 2016 USD USD USD Net income attributable to China Biologic Products Holdings, Inc. 128,056,302 67,943,035 104,779,307 Earnings allocated to participating nonvested shares (3,072,170 ) (2,188,633 ) (2,987,429 ) Net income used in basic and diluted earnings per ordinary share 124,984,132 65,754,402 101,791,878 Weighted average shares used in computing basic earnings per ordinary share 35,304,294 27,361,561 26,848,445 Diluted effect of stock option 128,665 244,062 400,699 Weighted average shares used in computing diluted earnings per ordinary share 35,432,959 27,605,623 27,249,144 Basic earnings per ordinary share 3.54 2.40 3.79 Diluted earnings per ordinary share 3.53 2.38 3.74

CHINA BIOLOGIC PRODUCTS HOLDI_2

CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. (PARENT COMPANY) (Tables)	12 Months Ended
	Dec. 31, 2018
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
CONDENSED BALANCE SHEETS	Condensed Balance Sheets: December 31, 2018 December 31, 2017 USD USD Cash 175,133,834 4,708,801 Time deposits 430,000,000 3,000,000 Prepayments and prepaid expenses 12,140,443 87,070 Total Current Assets 617,274,277 7,795,871 Property, plant and equipment, net 88 145 Investment in and amounts due from subsidiaries 1,139,337,487 634,245,590 Total Assets 1,756,611,852 642,041,606 Other payables and accrued expenses 4,544,071 3,559,211 Income tax payable - current 2,621,655 3,223,229 Total Current Liabilities 7,165,726 6,782,440 Income tax payable - non current 26,899,038 37,067,138 Other liabilities 497,489 - Total Liabilities 34,562,253 43,849,578 Total Shareholders’ Equity 1,722,049,599 598,192,028 Total Liabilities and Shareholders’ Equity 1,756,611,852 642,041,606
CONDENSED STATEMENTS OF COMPREHENSIVE INCOME	Condensed Statements of Comprehensive Income: For the Years Ended December 31, 2018 December 31, 2017 December 31, 2016 USD USD USD Equity in income of subsidiaries 132,337,339 137,099,797 124,187,590 General and administrative expenses (16,575,019 ) (28,879,890 ) (19,408,283 ) Other income 5,271,797 13,495 - Earnings before income tax expense 121,034,117 108,233,402 104,779,307 Income tax (benefits)/expense (7,022,185 ) 40,290,367 - Net Income 128,056,302 67,943,035 104,779,307
CONDENSED STATEMENTS OF CASH FLOWS	Condensed Statements of Cash Flows: For the Years Ended December 31, 2018 December 31, 2017 December 31, 2016 USD USD USD Net cash used in operating activities (6,211,606 ) (3,830,330 ) (2,400,188 ) Net cash used in investing activities (404,812,895 ) (3,000,000 ) - Net cash provided by financing activities 581,449,534 - - Net increase (decrease) in cash 170,425,033 (6,830,330 ) (2,400,188 ) Cash at beginning of year 4,708,801 11,539,131 13,939,319 Cash at end of year 175,133,834 4,708,801 11,539,131

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2018
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Schedule of Segment Reporting Information, by Segment	Segment information for the year ended and as of December 31, 2018 are as follows: Biopharmaceutical Products Biomaterial Products Total USD USD USD Year ended December 31, 2018 Sales 422,166,244 44,711,325 466,877,569 Cost of sales 141,683,089 5,104,147 146,787,236 Gross profit 280,483,155 39,607,178 320,090,333 Income from operations 128,980,355 17,192,396 146,172,751 Net income 131,561,108 16,406,007 147,967,115 Equity in income of an equity method investee 2,368,995 - 2,368,995 Interest income 13,704,954 1,796 13,706,750 Share-based compensation 23,130,570 - 23,130,570 Depreciation and Amortization 13,902,507 9,322,844 23,225,351 Income tax expense 15,353,208 2,682,972 18,036,180 Segment assets 2,095,996,321 348,885,628 2,444,881,949 Capital expenditures 35,245,016 1,471,374 36,716,390 Equity method investment 15,428,028 - 15,428,028
Reconciliation of Assets from Segment to Consolidated	Reconciliation of segment assets to consolidated total assets: December 31, 2018 USD Year ended December 31, 2018 Total segment assets 2,444,881,949 Elimination of intercompany investment balances (434,903,268 ) Consolidated total assets 2,009,978,681

DESCRIPTION OF BUSINESS AND S_2

DESCRIPTION OF BUSINESS AND SIGNIFICANT CONCENTRATIONS AND RISKS (Narrative) (Details)	12 Months Ended
	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016	Jan. 01, 2018
Basis Of Presentation Significant Concentration And Risk [Line Items]
Total cash at banks and deposits including insured amount	$ 951,336,787	$ 241,761,593
Cash, Insured Amount	$ 3,227,530	$ 2,577,139
Customers that individually comprised 10% or more of the total sales	0	0	0
Suppliers that comprised 10% or more of the total purchases	1	1	1
Customers represented 10% or more of trade receivables	0	0
Suppliers that represented more than 10% of accounts payables	0	1
Tianxinfu Beijing Medical Appliance Co Ltd [Member]
Basis Of Presentation Significant Concentration And Risk [Line Items]
Cost Method Investments				80.00%
Human Albumin [Member]
Basis Of Presentation Significant Concentration And Risk [Line Items]
Major product sales percentage	32.00%	35.80%	39.20%
Human Immunoglobulin For Intravenous Injection [Member]
Basis Of Presentation Significant Concentration And Risk [Line Items]
Major product sales percentage	24.30%	31.70%	34.60%

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	12 Months Ended
	Dec. 31, 2018USD ($)	Dec. 31, 2018CNY (¥)	Dec. 31, 2017USD ($)	Dec. 31, 2017CNY (¥)	Dec. 31, 2016USD ($)	Dec. 31, 2016CNY (¥)	Dec. 31, 2015USD ($)	Dec. 31, 2015CNY (¥)	Dec. 31, 2012USD ($)	Dec. 31, 2012CNY (¥)
Significant Accounting Policies [Line Items]
Research and development expenses	$ 9,524,412		$ 6,503,712		$ 7,021,992
Deferred Tax Assets, Net, Noncurrent	9,107,844		8,173,538
Equity Method Investment, Difference Between Carrying Amount and Underlying Equity	$ 1,192,320		1,252,387
Defined Contribution Plan Minimum Annual Contributions Per Employee Percent	25.00%	25.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	43.00%	43.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 5,581,682		3,763,276		3,258,629
Excess Tax Benefit from Share-based Compensation, Operating Activities	$ 0		$ 0		2,613,831
Xian Huitian Blood Products [Member]
Significant Accounting Policies [Line Items]
Equity method investment percentage	35.00%		35.00%
Accounting Standards Update 2015-17 [Member]
Significant Accounting Policies [Line Items]
Deferred Tax Assets, Net, Noncurrent					4,625,996
Accounting Standards Update 2016-09 [Member]
Significant Accounting Policies [Line Items]
Excess Tax Benefit from Share-based Compensation, Operating Activities			$ 621,381
Accounting Standards Update 2016-02 [Member]
Significant Accounting Policies [Line Items]
Operating Lease, Right-of-Use Asset	$ 2,000,000
Operating Lease, Liability	1,900,000
Guizhou Taibang [Member]
Significant Accounting Policies [Line Items]
Grants received									$ 2,989,215	¥ 18,350,000
Grants amortized amount	277,801		271,754		276,388
Shandong Taibang [Member]
Significant Accounting Policies [Line Items]
Grants received							$ 2,452,864	¥ 15,000,000
Grants amortized amount	227,085		222,143		410,369
Research and Development Expense [Member]
Significant Accounting Policies [Line Items]
Grants received	$ 704,795	¥ 4,837,300	$ 368,093	¥ 2,405,210	$ 728,874	¥ 5,056,361
Minimum [Member]
Significant Accounting Policies [Line Items]
Equity method investment percentage	20.00%
Contractual period of rights	40 years	40 years
Maximum [Member]
Significant Accounting Policies [Line Items]
Equity method investment percentage	50.00%
Contractual period of rights	50 years	50 years

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule Of Cash And Cash Equivalents) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents at banks	$ 337,810,153	$ 218,866,393
United States of America, Dollars
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents at banks	175,133,834	4,708,801
PRC Excluding Hong Kong [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents at banks	158,739,504	214,157,592
Hong Kong [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents at banks	$ 3,936,815	$ 0

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule Of Estimated Useful Lives Of The Assets) (Details)	12 Months Ended
	Dec. 31, 2018
Building [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	20 years
Building [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	45 years
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years

SUMMARY OF SIGNIFICANT ACCOUN_7

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES(Schedule of Acquired Finite-Lived Intangible Assets by Major Class) (Details)	12 Months Ended
	Dec. 31, 2018
Customer relationship
Finite-Lived Intangible Asset, Useful Life	7 years
Maximum [Member] | Permits and license
Finite-Lived Intangible Asset, Useful Life	10 years
Maximum [Member] | Customer relationship
Finite-Lived Intangible Asset, Useful Life	7 years
Maximum [Member] | Technical know-how
Finite-Lived Intangible Asset, Useful Life	12 years
Maximum [Member] | Others
Finite-Lived Intangible Asset, Useful Life	10 years
Minimum [Member] | Permits and license
Finite-Lived Intangible Asset, Useful Life	5 years
Minimum [Member] | Technical know-how
Finite-Lived Intangible Asset, Useful Life	3 years
Minimum [Member] | Others
Finite-Lived Intangible Asset, Useful Life	5 years

BUSINESS COMBINATION (Narrative

BUSINESS COMBINATION (Narrative) (Details) - USD ($)	Oct. 12, 2017	Dec. 31, 2018	Dec. 31, 2017
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	5,521,000
Business Acquisition, Percentage of Voting Interests Acquired	80.00%
Goodwill		$ 313,588,803	$ 0
Goodwill, Foreign Currency Translation Gain (Loss)		15,775,206
Business Combination Sale of Revenue		44,700,000
Business Combination Net Income Loss		16,400,000
Bio material Products [Member]
Goodwill		182,000,000
Bio pharmaceutical Products [Member]
Goodwill		$ 147,000,000
Tianxinfu Beijing Medical Appliance Co Ltd [Member]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		20.00%
In Process Research and Development [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		$ 1,254,937
Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		$ 54,956,664
Finite-Lived Intangible Asset, Useful Life		7 years
Technical Know how [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		$ 7,514,256
Maximum [Member] | Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life		7 years
Maximum [Member] | Technical Know how [Member]
Finite-Lived Intangible Asset, Useful Life		12 years
Minimum [Member] | Technical Know how [Member]
Finite-Lived Intangible Asset, Useful Life		3 years
PW Medtech Group Limited [Member]
Cost Method Investments	80.00%

BUSINESS COMBINATION (Schedule

BUSINESS COMBINATION (Schedule of Business Acquisitions, by Acquisition) (Details) - USD ($)	Dec. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
Goodwill	$ 313,588,803		$ 0
Tianxinfu Beijing Medical Appliance Co Ltd [Member]
Cash and cash equivalents		$ 97,702,278
Accounts receivable		312,832
Inventories		2,745,771
Other current assets		283,824
Property, plant and equipment		6,522,447
Land use rights		4,135,141
Intangible assets		63,725,856
Deferred income tax assets		480,334
Current liabilities		(6,129,418)
Deferred income tax liabilities		(10,382,902)
Fair value of noncontrolling interest		(53,871,002)
Goodwill		329,364,009
Total purchase consideration		$ 434,889,170

BUSINESS COMBINATION (Business

BUSINESS COMBINATION (Business Acquisition, Pro Forma Information) (Details) - Tianxinfu Beijing Medical Appliance Co Ltd [Member]	12 Months Ended
	Dec. 31, 2017USD ($)
Sales	$ 412,248,989
Net income	$ 100,749,486

ACCOUNTS RECEIVABLE (Schedule O

ACCOUNTS RECEIVABLE (Schedule Of Accounts Receivable) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 126,352,173	$ 77,858,266
Less: Allowance for doubtful accounts	(1,236,331)	(590,991)
Total	$ 125,115,842	$ 77,267,275

ACCOUNTS RECEIVABLE (Schedule_2

ACCOUNTS RECEIVABLE (Schedule Of Activity in the Allowance for Doubtful Accounts) (Details) - Accounts Receivable [Member] - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	$ 590,991	$ 533,596	$ 443,624
Provisions	655,148	23,783	123,239
Foreign currency translation adjustment	(9,808)	33,612	(33,267)
Ending balance	$ 1,236,331	$ 590,991	$ 533,596

PREPAYMENTS AND OTHER CURRENT_3

PREPAYMENTS AND OTHER CURRENT ASSETS (Narrative) (Details) - USD ($)	1 Months Ended
	Oct. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Other Receivables		$ 15,897,405	$ 10,412,739
Prepaid Expense		9,081,680	$ 4,886,604
Prepayment to an investment bank for a share repurchase program		$ 10,000,000
Stock Repurchase Program, Authorized Amount	$ 100,000,000
Stock Repurchase Program, Period in Force	6 months

PREPAYMENTS AND OTHER CURRENT_4

PREPAYMENTS AND OTHER CURRENT ASSETS (Schedule of activities in allowance for doubtful accounts) (Details) - Other Receivables And Prepayments [Member] - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Beginning balance	$ 4,960,020	$ 4,671,896	$ 4,924,063
Provisions	96,267	0	65,341
Foreign currency translation adjustment	(273,194)	288,124	(317,508)
Ending balance	$ 4,783,093	$ 4,960,020	$ 4,671,896

INVENTORIES (Narrative) (Detail

INVENTORIES (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Inventory Write-down	$ 0	$ 0	$ 256,862

INVENTORIES (Schedule Of Invent

INVENTORIES (Schedule Of Inventories) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Inventory [Line Items]
Raw materials	$ 124,408,741	$ 107,651,325
Work-in-process	57,457,153	42,202,306
Finished goods	61,429,618	59,717,204
Total	$ 243,295,512	$ 209,570,835

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Depreciation expense	$ 13,809,041	$ 11,691,731	$ 11,962,983
Gain (Loss) on Disposition of Assets	(1,001,000)	(3,228,845)	$ (293,098)
Shandong Taibang [Member]
Gain (Loss) on Disposition of Property Plant Equipment	$ (1,001,000)	$ (3,228,845)

PROPERTY, PLANT AND EQUIPMENT_3

PROPERTY, PLANT AND EQUIPMENT (Schedule Of Property Plant And Equipment) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	$ 218,105,583	$ 197,978,172
Construction in progress	7,713,523	105,226,787
Accumulated depreciation	(42,447,406)	(33,862,836)
Impairment of property, plant and equipment	(2,060,844)	0
Total property, plant and equipment, net	173,597,333	164,115,336
Prepayment for property, plant and equipment	4,730,028	2,697,413
Property, plant and equipment, net	178,327,361	166,812,749
Buildings [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	86,923,161	41,669,081
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	111,797,936	41,102,242
Furniture, Fixtures, Office Equipment and Vehicles [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	$ 11,670,963	$ 9,980,062

INTANGIBLE ASSETS (Narrative) (

INTANGIBLE ASSETS (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Amortization of Intangible Assets	$ 8,742,607	$ 497,344	$ 570,288

INTANGIBLE ASSETS (Schedule Of

INTANGIBLE ASSETS (Schedule Of Finite Lived Intangible Assets) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Intangible Assets, Gross (Excluding Goodwill)	$ 66,290,213	$ 5,352,761
Accumulated amortization	(13,031,342)	(4,816,423)
Total intangible assets, net	53,258,871	536,338
Permits and license [Member]
Intangible Assets, Gross (Excluding Goodwill)	4,579,081	4,809,764
Customer relationship [Member]
Intangible Assets, Gross (Excluding Goodwill)	52,320,870	0
Technical know-how [Member]
Intangible Assets, Gross (Excluding Goodwill)	7,153,870	0
In-process research and development assets [Member]
Intangible Assets, Gross (Excluding Goodwill)	1,194,740	0
Other [Member]
Intangible Assets, Gross (Excluding Goodwill)	$ 1,041,652	$ 542,997

INTANGIBLE ASSETS (Schedule O_2

INTANGIBLE ASSETS (Schedule Of Amortization Expense for Intangible Assets) (Details)	Dec. 31, 2018USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2,019	$ 8,115,855
2,020	8,108,251
2,021	8,107,674
2,022	8,103,936
2,023	8,040,120
Total	$ 40,475,836

RELATED PARTY TRANSACTIONS (Nar

RELATED PARTY TRANSACTIONS (Narrative) (Details) - USD ($)	1 Months Ended			6 Months Ended		9 Months Ended
	Nov. 30, 2018	Nov. 28, 2018	Aug. 24, 2018	Sep. 04, 2018	Aug. 24, 2018	Sep. 21, 2018	Dec. 31, 2018	Dec. 31, 2017	Oct. 12, 2017
Proceeds from Issuance of Private Placement					$ 590,000,000
Business Acquisition, Percentage of Voting Interests Acquired									80.00%
Prepayments for investments in equity securities							$ 10,812,893	$ 0
Beachhead Holdings Limited Centurium and Double Double Holdings Limited [Member]
Stock Issued During Period, Shares, New Issues					1,800,000
Number of Ordinary Shares Authorized to be Issued			3,050,000
Number of Additional Ordinary Shares Issued				1,250,000
PW Medtech Group Limited [Member]
Stock Issued During Period, Shares, New Issues						800,000
Number of Ordinary Shares Authorized to be Issued			800,000
Taijie Weiye Technology Co Ltd [Member]
Business Combination, Consideration Transferred		$ 10,812,893
Restrictions Period on Redemption Rights Business Acquisition Description		6 months from the third anniversary of the closing date of the transaction
Business Acquisition, Percentage of Voting Interests Acquired		11.55%
Description of Price for Redemption of Transferred Stake	which equals to the purchase price with an annual compounded interest of 6%.
CBP [Member]
Shares Issued, Price Per Share			$ 100.9		$ 100.9
Two Third Party Investors [Member]
Stock Issued During Period, Shares, New Issues					2,000,000
Number of Ordinary Shares Authorized to be Issued			2,000,000

LOAN RECEIVABLE (Narrative) (De

LOAN RECEIVABLE (Narrative) (Details)	1 Months Ended	12 Months Ended
	Aug. 31, 2015USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Aug. 31, 2015CNY (¥)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest income		$ 13,706,750	$ 7,623,624	$ 7,815,780
Loan Receivable Offset by Accounts Payable		$ 3,784,297	0	5,848,400
Xinjiang Deyuan [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Debt Instrument, Collateral		Deyuan Shareholder’s 58.02% equity interest in Xinjiang Deyuan.
Loan Receivable Offset by Accounts Payable		$ 3,784,297
Xinjiang Deyuan [Member] | Long-term Debt [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Cooperation Agreement Loan Principal Amount	$ 43,710,000				¥ 300,000,000
Debt Instrument, Interest Rate, Stated Percentage	6.00%				6.00%
Debt Instrument, Maturity Date	Jul. 31, 2018
Interest income		2,904,886	2,514,936	2,661,700
Interest Receivable Offset By Accounts Payable For The Purchase Of Plasma From Xinjiang Deyuan		2,062,426	0	675,933
Proceeds from Interest Received		$ 695,757	$ 2,514,936	$ 1,985,767

OTHER PAYABLES AND ACCRUED EX_3

OTHER PAYABLES AND ACCRUED EXPENSES (Narrative) (Details) - USD ($)		Dec. 31, 2018	Dec. 31, 2017
Accounts Payable And Accrued Liabilities [Line Items]
Payables To Guizhou Eakan Investing Corp	[1]	$ 2,121,392	$ 2,228,262
Potential Investors [Member]
Accounts Payable And Accrued Liabilities [Line Items]
Deposits received from a potential investor		4,977,112	5,227,846
Interest plus penalty on these deposits		$ 3,597,142	$ 3,451,227
[1]	Guizhou Taibang has payables to Guizhou Eakan Investing Corp., amounting to approximately $2,121,392 and $2,228,262 as of December 31, 2018 and 2017, respectively. The Company borrowed this interest free advance for working capital purpose for Guizhou Taibang. The balance is due on demand. See Note 17.

OTHER PAYABLES AND ACCRUED EX_4

OTHER PAYABLES AND ACCRUED EXPENSES (Schedule Of Other Payables And Accrued Expenses) (Details) - USD ($)		Dec. 31, 2018	Dec. 31, 2017
Accounts Payable And Accrued Liabilities [Line Items]
Payables to a potential investor	[1]	$ 8,574,254	$ 8,679,073
Payable to Guizhou Eakan Investing Corp	[2]	2,121,392	2,228,262
Salaries and bonuses payable		23,543,535	19,770,025
Accruals for sales promotion fee		29,401,827	19,346,659
Payables for construction work		8,181,773	9,135,810
Other tax payables		1,456,184	2,891,714
Advance from customers	[3]	9,101,834	2,425,975
Deposits received		7,463,172	4,434,443
Others		10,089,822	6,915,903
Total		$ 99,933,793	$ 75,827,864
[1]	The payables to a potential investor comprises deposits received from a potential investor in the amount of $4,977,112 and $5,227,846 as of December 31, 2018 and 2017, respectively, and related interest plus penalty on these deposits totaling $3,597,142 and $3,451,227 as of December 31, 2018 and 2017, respectively.
[2]	Guizhou Taibang has payables to Guizhou Eakan Investing Corp., amounting to approximately $2,121,392 and $2,228,262 as of December 31, 2018 and 2017, respectively. The Company borrowed this interest free advance for working capital purpose for Guizhou Taibang. The balance is due on demand. See Note 17.
[3]	The change in advance from customers primarily represents the cash received, less amounts recognized as sales during the year.

INCOME TAX (Narrative) (Details

INCOME TAX (Narrative) (Details)	1 Months Ended			3 Months Ended	12 Months Ended					36 Months Ended		120 Months Ended
	Aug. 31, 2018USD ($)	Dec. 22, 2017USD ($)	Jan. 31, 2008	Jun. 30, 2018USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2018CNY (¥)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2016CNY (¥)	Dec. 31, 2019	Dec. 31, 2016USD ($)	Dec. 31, 2020	Dec. 31, 2018CNY (¥)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Deferred tax assets for tax loss carryforwards					$ 4,300,813		$ 5,031,657
Deferred Tax Assets, Valuation Allowance					4,300,813		$ 5,031,657	$ 26,629,179			$ 26,629,179			$ 8,160,611
Subject to withholding tax at 10%, unless reduced by tax treaties			10.00%
Deferred tax liabilities on undistributed earnings															$ 7,351,023
Underpayment of taxes					14,570								¥ 100,000
Income Tax Paid On Repatriated Earnings				$ 3,250,000
Taibang Holdings [Member]
Deferred Tax Liabilities, Reversed Amount					2,310,512			1,265,733			$ 1,265,733
Shandong Taibang Biological Products Co., Ltd [Member]
Preferential tax rate											15.00%
Undistributed earnings															$ 74,000,000
Distributed Earnings					$ 21,674,332	¥ 148,760,000		$ 11,929,854	¥ 82,760,000
Shandong Taibang Biological Products Co., Ltd [Member] | Scenario, Forecast [Member]
Preferential tax rate										15.00%
Guizhou Taibang Biological Products Co., Ltd [Member] | Scenario, Forecast [Member]
Income Tax Rate												15.00%
Health Forward Holdings Limited [Member]
Income Tax Rate					16.50%	16.50%
Tianxinfu Beijing Medical Appliance Co Ltd [Member] | Scenario, Forecast [Member]
Preferential tax rate												15.00%
PRC [Member]
Income Tax Rate					25.00%	25.00%
The United States of America [Member]
Income Tax Rate							35.00%
Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount		$ 40,300,000
Current Income Tax Expense (Benefit)	$ (7,500,000)
Hong Kong [Member]
Income Tax Rate					16.50%	16.50%	16.50%	16.50%	16.50%
PRC subsidiaries [Member]
Deferred tax assets for tax loss carryforwards					$ 4,300,813
Tax loss carryforwards					18,526,347
Deferred Tax Assets, Valuation Allowance					4,300,813		$ 5,031,657
Undistributed earnings					613,600,000
PRC subsidiaries [Member] | 2019 [Member]
Tax loss carryforwards expiring					4,806,145
PRC subsidiaries [Member] | 2020 [Member]
Tax loss carryforwards expiring					4,204,366
PRC subsidiaries [Member] | 2021 [Member]
Tax loss carryforwards expiring					4,644,148
PRC subsidiaries [Member] | 2022 [Member]
Tax loss carryforwards expiring					728,172
PRC subsidiaries [Member] | 2023 [Member]
Tax loss carryforwards expiring					$ 4,143,516

SCHEDULE OF EARNINGS (LOSSES) B

SCHEDULE OF EARNINGS (LOSSES) BEFORE INCOME TAXES BY JURISDICTIONS (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
PRC, excluding Hong Kong	$ 175,225,854	$ 171,787,763	$ 170,830,607
U.S.	(11,303,223)	(28,866,395)	(19,408,283)
BVI	2,341,136	3,488,680	2,498,629
Hong Kong	(260,472)	(2,280)	(1,712)
Total	$ 166,003,295	$ 146,407,768	$ 153,919,241

SCHEDULE OF INCOME TAX EXPENSE

SCHEDULE OF INCOME TAX EXPENSE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Deferred income tax benefit	$ (4,159,890)	$ (3,252,516)	$ (3,006,541)
Total income tax expense	18,036,180	64,171,809	25,125,820
People Republic China [Member]
Current income tax expense	29,715,744	27,133,958	28,132,361
Deferred income tax benefit	(4,657,379)	(3,252,516)	(3,006,541)
US [Member]
Current income tax expense	(7,519,674)	40,290,367	0
Deferred income tax benefit	$ 497,489	$ 0	$ 0

SCHEDULE OF RECONCILIATION OF I

SCHEDULE OF RECONCILIATION OF INCOME TAX EXPENSE (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
PRC statutory income tax rate	25.00%	25.00%	25.00%
Non-deductible expenses:
Share-based compensation	1.40%	3.70%	0.00%
Others	0.90%	1.10%	1.60%
Tax rate differential	(0.50%)	(0.90%)	(3.60%)
Effect of PRC preferential tax rate	(9.00%)	(11.10%)	(10.90%)
Bonus deduction on research and development expenses	(2.30%)	(1.50%)	(1.50%)
Change in valuation allowance	0.40%	(0.60%)	5.30%
Repatriation tax	(4.50%)	29.40%	0.00%
Tax effect of equity method investment	0.30%	(0.60%)	0.40%
Excess tax benefits from stock option exercises	(0.80%)	(0.70%)	0.00%
Effective income tax rate	10.90%	43.80%	16.30%

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Deferred income tax assets arising from:
-Accrued expenses	$ 7,587,118	$ 6,558,359
-Deferred income	213,086	258,255
-Property, Plant and Equipment	1,149,033	1,210,006
-Other non-current assets	158,607	146,918
-Tax loss carryforwards	4,300,813	5,031,657
Gross deferred income tax assets	13,408,657	13,205,195
Less: valuation allowance	(4,300,813)	(5,031,657)
Net deferred income tax assets	9,107,844	8,173,538
Deferred income tax liabilities arising from:
- Property, plant and equipment	(129,636)	0
- Intangible assets	(7,947,786)	(148,467)
- Land use rights	(552,602)	0
- Equity method investment	(497,489)	0
- Dividend withholding tax	(3,774,778)	(6,085,290)
Deferred income tax liabilities	(12,902,291)	(6,233,757)
Classification on consolidated balance sheets:
Deferred income tax assets, included in other non-current assets	9,107,844	8,173,538
Deferred income tax liabilities, included in other liabilities	$ (12,902,291)	$ (6,233,757)

SUMMARY OF VALUATION ALLOWANCE

SUMMARY OF VALUATION ALLOWANCE FOR DEFERRED TAX ASSETS (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Beginning balance	$ 5,031,657	$ 26,629,179	$ 8,160,611
Addition (deduction) during the year	(507,897)	(21,927,117)	18,676,456
Foreign currency translation adjustment	(222,947)	329,595	(207,888)
Ending balance	$ 4,300,813	$ 5,031,657	$ 26,629,179

OPTIONS AND NONVESTED SHARES (N

OPTIONS AND NONVESTED SHARES (Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended
	May 09, 2008	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Warrants and Options Disclosure [Line Items]
Stock compensation expense to be recognized with respect to non-vested shares		$ 44,891,282
Stock compensation expense with respect to non-vested shares weighted average vesting period		2 years 3 months 25 days
General and Administrative Expense [Member]
Warrants and Options Disclosure [Line Items]
Stock compensation expense with respect to stock options		$ 0	$ 0	$ 649,203
Stock compensation expense with respect to nonvested shares		$ 23,130,570	$ 33,903,283	$ 23,756,308
2008 Equity Incentive Plan [Member]
Warrants and Options Disclosure [Line Items]
Stock Incentive Option Granted Percentage	10.00%
Fair Value Market Exercise Price Percentage	110.00%
Options granted terms	10 years

SCHEDULE OF STOCK OPTIONS ACTIV

SCHEDULE OF STOCK OPTIONS ACTIVITY (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding at beginning	229,249	314,491	651,897
Number of Options, Granted	0	0	0
Number of Options, Exercised	(121,945)	(85,242)	(337,406)
Number of Options, Forfeited and expired	0	0	0
Number of Options, Outstanding at ending	107,304	229,249	314,491	651,897
Number of Options, Vested	107,304
Number of Options, Exercisable	107,304
Weighted Average Exercise Price, Outstanding at beginning	$ 10.37	$ 10.32	$ 10.44
Weighted Average Exercise Price, Granted	0	0	0
Weighted Average Exercise Price, Exercised	9.71	10.18	10.55
Weighted Average Exercise Price, Forfeited and expired	0	0		$ 0
Weighted Average Exercise Price, Outstanding	11.13	$ 10.37	$ 10.32	$ 10.44
Weighted Average Exercise Price, Vested	11.13
Weighted Average Exercise Price, Exercisable	$ 11.13
Weighted Average Remaining Contractual Term in Years, Outstanding	2 years 3 months 11 days	2 years 7 months 10 days	3 years 10 months 2 days	5 years 2 months 26 days
Weighted Average Remaining Contractual Term in Years, Vested	2 years 3 months 11 days
Weighted Average Remaining Contractual Term in Years, Exercisable	2 years 3 months 11 days
Aggregate Intrinsic Value, Outstanding at beginning	$ 15,168,276	$ 30,568,083	$ 86,064,461
Aggregate Intrinsic Value, Exercised	(9,137,231)	(7,868,258)	(35,180,367)
Aggregate Intrinsic Value, Outstanding	7,570,681	$ 15,168,276	$ 30,568,083	$ 86,064,461
Aggregate Intrinsic Value, Vested	7,570,681
Aggregate Intrinsic Value, Exercisable	$ 7,570,681

SCHEDULE OF NONVESTED SHARES AC

SCHEDULE OF NONVESTED SHARES ACTIVITY (Details) - Non Vested Shares [Member] - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of nonvested shares, Outstanding at beginning	914,026	912,650	669,100
Number of nonvested shares, Granted	333,620	356,150	511,200
Number of nonvested shares, Vested	(256,830)	(353,694)	(255,150)
Number of nonvested shares, Forfeited	(385,425)	(1,080)	(12,500)
Number of nonvested shares, Outstanding at ending	605,391	914,026	912,650
Grant date weighted average fair value, Outstanding at beginning	$ 103.95	$ 104.51	$ 77.49
Grant date weighted average fair value, Granted	79.23	89.94	119.75
Grant date weighted average fair value, Vested	100.91	91.32	66.04
Grant date weighted average fair value, Forfeited	98.86	98.20	66.74
Grant date weighted average fair value, Outstanding at ending	$ 94.85	$ 103.95	$ 104.51

STATUTORY RESERVES (Narrative)

STATUTORY RESERVES (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Statutory Accounting Practices [Line Items]
Allocate at least 10% of its after tax profits	10.00%	10.00%
Until the reserve balance reaches 50% of respective registered capital	50.00%	50.00%
Statutory Accounting Practices, Statutory Capital and Surplus, Balance	$ 53,358,414	$ 34,513,788
PRC subsidiaries [Member]
Statutory Accounting Practices [Line Items]
Appropriations To The Reserve Fund	$ 18,844,626	$ 5,051	$ 348,583

FAIR VALUE MEASUREMENTS (Narra

FAIR VALUE MEASUREMENTS (Narrative) (Details)	12 Months Ended
	Dec. 31, 2018
Maximum [Member]
Fair value of Short term Invetments Return Percentage	4.65%
Minimum [Member]
Fair value of Short term Invetments Return Percentage	3.00%

SCHEDULE OF SALES BY PRODUCT TY

SCHEDULE OF SALES BY PRODUCT TYPE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Product Information [Line Items]
Sales	$ 466,877,569	$ 370,406,840	$ 341,169,426
Biomaterial products [Member]
Product Information [Line Items]
Sales	44,711,325	0	0
Biopharmaceutical products [Member]
Product Information [Line Items]
Sales	422,166,244	370,406,840	341,169,426
Human Albumin [Member] | Biopharmaceutical products [Member]
Product Information [Line Items]
Sales	149,369,846	132,498,791	133,712,663
Human Immunoglobulin For Intravenous Injection [Member] | Biopharmaceutical products [Member]
Product Information [Line Items]
Sales	113,490,790	117,511,797	117,891,410
Other Immunoglobulin Products [Member] | Biopharmaceutical products [Member]
Product Information [Line Items]
Sales	59,470,912	50,147,328	40,105,561
Others [Member] | Biopharmaceutical products [Member]
Product Information [Line Items]
Sales	31,677,439	21,049,636	17,281,111
Placenta Polypeptide [Member] | Biopharmaceutical products [Member]
Product Information [Line Items]
Sales	68,157,257	49,199,288	32,178,681
Artificial Dura Mater [Member] | Biomaterial products [Member]
Product Information [Line Items]
Sales	40,644,561	0	0
Others [Member] | Biomaterial products [Member]
Product Information [Line Items]
Sales	$ 4,066,764	$ 0	$ 0

SCHEDULE OF SALES BY CHANNEL TY

SCHEDULE OF SALES BY CHANNEL TYPE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenues	$ 466,877,569	$ 370,406,840	$ 341,169,426
Plasma Products [Member]
Revenues	354,008,987	321,207,552	308,990,745
Biopharmaceutical products [Member]
Revenues	422,166,244	370,406,840	341,169,426
Biomaterial products [Member]
Revenues	44,711,325	0	0
Distributors [Member] | Plasma Products [Member]
Revenues	174,698,620	126,381,596	120,297,097
Distributors [Member] | Placenta Polypeptide [Member]
Revenues	68,157,257	49,199,288	32,178,681
Distributors [Member] | Biomaterial products [Member]
Revenues	42,717,750	0	0
Hospitals and inoculation centers [Member] | Plasma Products [Member]
Revenues	179,310,367	194,825,956	188,693,648
Hospitals [Member] | Biomaterial products [Member]
Revenues	$ 1,993,575	$ 0	$ 0

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details)	Dec. 31, 2018USD ($)
Contractual Obligations, Less than one year	$ 24,082,433
Contractual Obligations, One to two years	29,888,255
Contractual Obligations, Two to three years	16,457,448
Contractual Obligations, Three to four years	4,095
Contractual Obligations, Four to five years	4,095
Purchase of plasma commitment [Member]
Contractual Obligations, Less than one year	14,018,867	[1]
Contractual Obligations, One to two years	27,925,833	[1]
Contractual Obligations, Two to three years	16,290,070	[1]
Contractual Obligations, Three to four years	0	[1]
Contractual Obligations, Four to five years	0	[1]
Capital commitment [Member]
Contractual Obligations, Less than one year	9,214,835
Contractual Obligations, One to two years	1,023,871
Contractual Obligations, Two to three years	0
Contractual Obligations, Three to four years	0
Contractual Obligations, Four to five years	0
Operating lease commitment [Member]
Contractual Obligations, Less than one year	848,731
Contractual Obligations, One to two years	938,551
Contractual Obligations, Two to three years	167,378
Contractual Obligations, Three to four years	4,095
Contractual Obligations, Four to five years	$ 4,095
[1]	See Note 10.

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Narrative) (Details)		6 Months Ended
		Jun. 30, 2017USD ($)	Jun. 30, 2017CNY (¥)	Dec. 31, 2018USD ($)	Dec. 31, 2018CNY (¥)	Dec. 31, 2017USD ($)	Jun. 30, 2017CNY (¥)	May 30, 2007CNY (¥)
Payables To Guizhou Eakan Investing Corp	[1]			$ 2,121,392		$ 2,228,262
Operating Lease [Member]
Operating Leases, Future Minimum Payments Due				2,129,052
Plasma [Member]
Operating Leases, Future Minimum Payments Due				58,234,770
Capital Addition Purchase Commitments [Member]
Operating Leases, Future Minimum Payments Due				10,238,706
PRC Lawsuit [Member]
Plaintiff alleged | ¥								¥ 14,560,000
Payables To Guizhou Eakan Investing Corp		$ 2,121,392		$ 2,121,392	¥ 14,560,000		¥ 14,560,000
Fund Possession Cost		$ 5,411,531	¥ 37,141,600
[1]	Guizhou Taibang has payables to Guizhou Eakan Investing Corp., amounting to approximately $2,121,392 and $2,228,262 as of December 31, 2018 and 2017, respectively. The Company borrowed this interest free advance for working capital purpose for Guizhou Taibang. The balance is due on demand. See Note 17.

EARNINGS PER SHARE (Schedule Of

EARNINGS PER SHARE (Schedule Of Computation Of Basic And Diluted Net Income Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Net income attributable to China Biologic Products Holdings, Inc.	$ 128,056,302	$ 67,943,035	$ 104,779,307
Earnings allocated to participating nonvested shares	(3,072,170)	(2,188,633)	(2,987,429)
Net income used in basic and diluted earnings per ordinary share	$ 124,984,132	$ 65,754,402	$ 101,791,878
Weighted average shares used in computing basic earnings per ordinary share	35,304,294	27,361,561	26,848,445
Diluted effect of stock option	128,665	244,062	400,699
Weighted average shares used in computing diluted earnings per ordinary share	35,432,959	27,605,623	27,249,144
Basic earnings per ordinary share	$ 3.54	$ 2.40	$ 3.79
Diluted earnings per ordinary share	$ 3.53	$ 2.38	$ 3.74

SCHEDULE OF CONDENSED BALANCE S

SCHEDULE OF CONDENSED BALANCE SHEETS (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Financial Information Disclosure [Line Items]
Cash	$ 338,880,559	$ 219,336,848	$ 183,765,533	$ 144,937,893
Prepayments and prepaid expenses	9,081,680	4,886,604
Total Current Assets	1,357,187,822	593,121,611
Property, plant and equipment, net	178,327,361	166,812,749
Total Assets	2,009,978,681	809,057,417
Other payables and accrued expenses	99,933,793	75,827,864
Income tax payable - current	11,010,347	14,258,544
Total Current Liabilities	122,348,782	97,635,317
Income tax payable - non current	26,899,038	37,067,138
Other liabilities	13,203,485	6,553,088
Total Liabilities	165,275,517	144,732,420
Total Shareholders' Equity	1,722,049,599	598,192,028
Total Liabilities and Shareholders' Equity	2,009,978,681	809,057,417
Parent [Member]
Financial Information Disclosure [Line Items]
Cash	175,133,834	4,708,801	$ 11,539,131	$ 13,939,319
Time Deposits	430,000,000	3,000,000
Prepayments and prepaid expenses	12,140,443	87,070
Total Current Assets	617,274,277	7,795,871
Property, plant and equipment, net	88	145
Investment in and amounts due from subsidiaries	1,139,337,487	634,245,590
Total Assets	1,756,611,852	642,041,606
Other payables and accrued expenses	4,544,071	3,559,211
Income tax payable - current	2,621,655	3,223,229
Total Current Liabilities	7,165,726	6,782,440
Income tax payable - non current	26,899,038	37,067,138
Other liabilities	497,489	0
Total Liabilities	34,562,253	43,849,578
Total Shareholders' Equity	1,722,049,599	598,192,028
Total Liabilities and Shareholders' Equity	$ 1,756,611,852	$ 642,041,606

SCHEDULE OF CONDENSED STATEMENT

SCHEDULE OF CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Statements Of Comprehensive Income [Line Items]
Equity in income (loss) of subsidiaries	$ 2,368,995	$ 3,509,071	$ 2,519,201
General and administrative expenses	(68,817,340)	(67,683,667)	(54,519,122)
Other income (expenses)	(4,092,935)	0	0
Earnings before income tax expense	166,003,295	146,407,768	153,919,241
Income tax expense	(18,036,180)	(64,171,809)	(25,125,820)
Net Income	147,967,115	82,235,959	128,793,421
Parent [Member]
Statements Of Comprehensive Income [Line Items]
Equity in income (loss) of subsidiaries	132,337,339	137,099,797	124,187,590
General and administrative expenses	(16,575,019)	(28,879,890)	(19,408,283)
Other income (expenses)	5,271,797	13,495	0
Earnings before income tax expense	121,034,117	108,233,402	104,779,307
Income tax expense	(7,022,185)	40,290,367	0
Net Income	$ 128,056,302	$ 67,943,035	$ 104,779,307

SCHEDULE OF CONDENSED STATEME_2

SCHEDULE OF CONDENSED STATEMENTS OF CASH FLOWS (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash Flow Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	$ 103,941,952	$ 102,183,885	$ 123,258,611
Net cash used in investing activities	(558,945,397)	(60,895,217)	(52,520,361)
Net cash provided by (used in) financing activities	571,304,139	(18,324,385)	(22,083,938)
Net increase (decrease) in cash	119,543,711	35,571,315	38,827,640
Cash and cash equivalents at beginning of year	219,336,848	183,765,533	144,937,893
Cash and cash equivalents at end of year	338,880,559	219,336,848	183,765,533
Parent [Member]
Cash Flow Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	(6,211,606)	(3,830,330)	(2,400,188)
Net cash used in investing activities	(404,812,895)	(3,000,000)	0
Net cash provided by (used in) financing activities	581,449,534	0	0
Net increase (decrease) in cash	170,425,033	(6,830,330)	(2,400,188)
Cash and cash equivalents at beginning of year	4,708,801	11,539,131	13,939,319
Cash and cash equivalents at end of year	$ 175,133,834	$ 4,708,801	$ 11,539,131

CAPITAL WITHDRAWAL BY TWO FOR_2

CAPITAL WITHDRAWAL BY TWO FORMER NONCONTROLLING INTEREST SHAREHOLDRERS OF GUIZHOU TAIBANG (Narrative) (Details) - Dispute With Jiean Over Certain Capital Injection Into Guizhou Taibang [Member]	1 Months Ended
	Oct. 26, 2016USD ($)	Oct. 26, 2016CNY (¥)
Equity Method Investment, Ownership Percentage	15.30%	15.30%
Consideration To Noncontrolling Interest Holders For Withdraw All Of Capital Contribution	$ 58,091,018	¥ 415,000,000

SEGMENT INFORMATION - (Schedule

SEGMENT INFORMATION - (Schedule of Segment Reporting Information by Segment) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Sales	$ 466,877,569	$ 370,406,840	$ 341,169,426
Cost of sales	146,787,236	125,517,021	124,034,448
Gross profit	320,090,333	244,889,819	217,134,978
Income from operations	146,172,751	135,858,505	143,914,622
Net income	147,967,115	82,235,959	128,793,421
Equity in income of an equity method investee	2,368,995	3,509,071	2,519,201
Interest income	13,706,750	7,623,624	7,815,780
Share-based compensation	23,130,570	33,903,283	24,405,511
Depreciation and Amortization	23,225,351
Income tax expense	18,036,180	64,171,809	25,125,820
Segment Assets	2,444,881,949
Capital expenditures	36,716,390
Equity method investment	15,428,028	14,903,908
Bio pharmaceutical Products [Member]
Sales	422,166,244	370,406,840	341,169,426
Cost of sales	141,683,089
Gross profit	280,483,155
Income from operations	128,980,355
Net income	131,561,108
Equity in income of an equity method investee	2,368,995
Interest income	13,704,954
Share-based compensation	23,130,570
Depreciation and Amortization	13,902,507
Income tax expense	15,353,208
Segment Assets	2,095,996,321
Capital expenditures	35,245,016
Equity method investment	15,428,028
Bio material Products [Member]
Sales	44,711,325	$ 0	$ 0
Cost of sales	5,104,147
Gross profit	39,607,178
Income from operations	17,192,396
Net income	16,406,007
Equity in income of an equity method investee	0
Interest income	1,796
Share-based compensation	0
Depreciation and Amortization	9,322,844
Income tax expense	2,682,972
Segment Assets	348,885,628
Capital expenditures	1,471,374
Equity method investment	$ 0

SEGMENT INFORMATION - (Reconcil

SEGMENT INFORMATION - (Reconciliation of Assets from Segment to Consolidated) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Total segment assets	$ 2,444,881,949
Elimination of intercompany investment balances	(434,903,268)
Total Assets	$ 2,009,978,681	$ 809,057,417

SUBSEQUENT EVENTS (Narrative) (

SUBSEQUENT EVENTS (Narrative) (Details)	1 Months Ended
	Jan. 31, 2019USD ($)	Jan. 31, 2019CNY (¥)	Mar. 04, 2019USD ($)	Oct. 30, 2018USD ($)
Subsequent Event [Line Items]
Stock Repurchase Program, Authorized Amount				$ 100,000,000
Subsequent Event [Member] | Previously Announced Share Repurchase Program [Member]
Subsequent Event [Line Items]
Stock Repurchase Program, Authorized Amount			$ 100,000,000
Subsequent Event [Member] | PRC Legal Proceedings [Member]
Subsequent Event [Line Items]
Guizhou Taibang's equity interests	4.71%	4.71%
Payment to Guizhou Taibang in exchange	$ 1,631,840	¥ 11,200,000